Entries |
Document | Title | Date |
20080206135 | Method for monitoring blood flow and metabolic uptake in tissue with radiolabeled alkanoic acid - The present invention relates to novel modified fatty acid analogs, where a positron or gamma-emitting label is placed at a position on a fatty acid backbone and an organic substituent is substituted at the 2,3; 3,4; 4,5; 5,6 and other sequence positions of a fatty acid backbone. These novel fatty acid analogs are designed to enter the tissues of interest by the same long chain fatty acid carrier mechanism as natural fatty acids, however, functional substituents in the 2,3; 3,4; 4,5; 5,6 and other sequence positions, block the catabolic pathway, thus trapping these analogs in a virtually unmodified form in the tissues of interest. | 08-28-2008 |
20080213173 | Method for monitoring blood flow and metabolic uptake in tissue with radiolabeled alkanoic acid - The present invention relates to novel modified fatty acid analogs, where a positron or gamma-emitting label is placed at a position on a fatty acid backbone and an organic substituent is substituted at the 2,3; 3,4; 4,5; 5,6 and other sequence positions of a fatty acid backbone. These novel fatty acid analogs are designed to enter the tissues of interest by the same long chain fatty acid carrier mechanism as natural fatty acids, however, functional substituents in the 2,3; 3,4; 4,5; 5,6 and other sequence positions, block the catabolic pathway, thus trapping these analogs in a virtually unmodified form in the tissues of interest. | 09-04-2008 |
20080219921 | Novel Technetium and Rhenium Complexes. - Novel radioactive technetium and rhenium complexes comprising tripodal ligands are provided by the present invention. In particular, Tc(I) complexes are provided by the present invention. Novel ligands suitable for the formation of the technetium and rhenium complexes of the invention are also provided, as well as radiopharmaceutical compositions comprising said complexes, kits for their preparation. The invention also relates to the us of | 09-11-2008 |
20080219922 | Alzheimer's Disease Imaging Agents - This invention provides compounds and methods of imaging amyloid deposits using radiolabeled compounds. This invention also provides a method of inhibiting the aggregation of amyloid proteins to form amyloid plaques or deposits, a method of determining a therapeutic compound's ability to inhibit aggregation of amyloid protein, and a method of delivering a therapeutic agent to amyloid deposits. | 09-11-2008 |
20080226550 | SMALL TECHNETIUM-99M AND RHENIUM LABELED AGENTS AND METHODS FOR IMAGING TUMORS - The present invention relates to compounds and related technetium and rhenium complexes thereof which are suitable for imaging or therapeutic treatment of tumors, e.g., carcinomas, melanomas and other tumors. In another embodiment, the invention relates to methods of imaging tumors using radiolabeled metal complexes. Preferred radiolabeled complexes for imaging tumors include technetium and rhenium complexes. The high tumor uptake and significant tumor/nontumor ratios of the technetium complexes of the invention indicate that such small technetium-99m-based molecular probes can be developed as in-vivo diagnostic agents for melanoma and its metastases. In yet another embodiment, the invention relates to methods of treatment of tumors using a radiolabeled metal complex as a radiopharmaceutical agent to treat the tumor. | 09-18-2008 |
20080233047 | Symmetric and Asymmetric Halogen-Containing Metallocarboranylporphyrins and Uses Thereof - The present invention is directed to low toxicity boronated compounds and methods for their use in the treatment, visualization, and diagnosis of tumors. More specifically, the present invention is directed to low toxicity halogenated, carborane-containing 5,10,15,20-tetraphenylporphyrin compounds and methods for their use particularly in boron neutron capture therapy (BNCT) and photodynamic therapy (PDT) for the treatment of tumors of the brain, head and neck, and surrounding tissue. The invention is also directed to using these halogenated, carborane-containing tetraphenylporphyrin compounds in methods of tumor imaging and/or diagnosis such as MRI, SPECT, or PET. | 09-25-2008 |
20080267866 | Novel Antiviral Macrocycle Derivatives and Metal Complexes, Incorporating Bridged Macrocycles - A compound of Formulae (1), (2) or (3), A | 10-30-2008 |
20080279769 | Enzyme Inhibitor Imaging Agents - The present invention discloses that imaging agents which comprise a specific type of matrix metalloproteinase inhibitors (MMPi's) of the hydroxamate class labelled with an imaging moiety, are useful diagnostic imaging agents for in vivo imaging and diagnosis of the mammalian body. | 11-13-2008 |
20080279770 | Metal Complexes Based on Tetrathiol Ligands and Their Use in Nuclear Medical Diagnostics and Endoradionuclide Therapy and Method For Producing Said Metal Complexes - The aim of the invention is to provide radiolytically and metabolically stable metal complexes suitable for conjugation with biomolecules and, therefore, useful for nuclear medical diagnostics and in endoradionuclide therapy and to provide a method for their production. This is achieved by metal complexes based on tetrathiol ligands of formula (I), in which (CH—R | 11-13-2008 |
20080292547 | Novel Imaging Agents for Fibrosis - The present invention provides a novel imaging agent suitable for the non-invasive visualization of fibrosis. A method for the preparation of the imaging agent is also provided by the invention, as well as a precursor for use in said method. Also provided is a pharmaceutical composition comprising the imaging agent and a kit for the preparation of the pharmaceutical. In a further aspect, use of the imaging agent for in vivo imaging and in the preparation of a medicament for the diagnosis of a condition in which LOX is upregulated is provided. | 11-27-2008 |
20080299038 | Luminescent Metal Complexes for Monitoring Renal Function - Some embodiments of the present invention may be said to be directed to metal complexes of Formula I, wherein at least one of X | 12-04-2008 |
20080305039 | Facilitated Transport of Bisphosphonates by Vitamin C - Compounds of the formula: are described wherein: A | 12-11-2008 |
20080305040 | In Vivo or in Vitro Method For Detecting Amyloid Deposits Having at Least One Amyloidogenic Protein - An amyloid deposit can be detected by administering to a subject or applying to a sample a compound of Formula (I) or Formula (II) or structures 1-45, as described, and then imaging to detect binding of the compound to an amyloid deposit, where the amyloido genie protein of the deposit can be AL, AH, ATTR, Aβ2M, AA, AApoAI, AApoAII, AGeI, ALys, AFib, ACys, ABri, ADan, APrP, ACaI, AlAPP, AANF, APro, AIns, AMed, AKer, A(tbn), and/or ALac. | 12-11-2008 |
20090060836 | DERIVATIVES OF 2-NITRO-1,3-IMIDAZOLE COUPLED TO AMINO ACIDS AND DEOXYRIBOSE USEFUL FOR THE DETECTION OF HYPOXIC BIOLOGICAL TISSUE - The present invention relates to a 2-nitroimidazole derivative, a diagnostic pharmaceutical composition which contains such 2-nitroimidazole derivative, the use of the 2-nitroimidazole derivative for the detection of hypoxic biological tissue as well a method for the detection of hypoxic biological tissue by the use of the 2-nitroimidazole derivative. | 03-05-2009 |
20090081123 | PHARMACEUTICAL COMPOUNDS - Tricyclic pyrazole derivatives of the following formula (I) having affinity for the cannabinoidergic CB1 and/or CB2 receptors: | 03-26-2009 |
20090087376 | Heterocyclic Dye Compounds For In Vivo Imaging And Diagnosis Of Alzheimer's Disease - The present invention relates to the identification of compounds that are suitable for imaging amyloid deposits in living patients. The invention relates, in part, to a method of imaging amyloid deposits in brain in vivo to allow antemortem diagnosis of Alzheimer's disease. The present invention also relates to therapeutic uses for such compounds, as exemplified by compounds of the formula (1) in which Y is independently S, O, or N and m is 1, 2, or 3. | 04-02-2009 |
20090087377 | COMPOSITIONS FOR TARGETED IMAGING AND THERAPY - The present invention relates to the field of radiochemistry, nuclear imaging, radionuclide therapy and chemical synthesis. More particularly, it concerns a strategy for radiolabeling target ligands. It further concerns methods of using those radiolabeled ligands for imaging, radionuclide therapy and tissue-specific disease imaging. | 04-02-2009 |
20090092547 | Injectable Particles - According to an aspect of the invention, injectable polymeric particles are provided which contain branched poly(vinyl alcohol). Other aspects of the invention pertain to methods of making such particles. Still other aspects of the invention pertain to injectable compositions that comprise such particles and to methods of treatment that employ such injectable compositions. | 04-09-2009 |
20090104116 | COMPOUNDS FOR THE INHIBITION OF INTEGRINS AND USE THEREOF -
The present invention is related to a compound of formula (I), wherein A is a nonaromatic heterocyclic ring, Ar is either absent or phenylene; Ψ is a radical of formula (II), R | 04-23-2009 |
20090117040 | Novel pharmaceutical and diagnostic compositions for use in the treatment and diagnosis of neurodegenerative diseases or amyloid diseases - The present invention relates to pharmaceutical and diagnostic compositions as well as to the use of the active substances contained therein for preparing a pharmaceutical or a diagnostic composition for the treatment or diagnosis of neurodegenerative disorders or amyloid diseases. | 05-07-2009 |
20090123369 | Styrylpyridine Derivatives and Their Use for Binding and Imaging Amyloid Plaques - This invention relates to a method of imaging amyloid deposits and to styrylpyridine compounds, and methods of making radiolabeled styrylpyridine compounds useful in imaging amyloid deposits. This invention also relates to compounds, and methods of making compounds for inhibiting the aggregation of amyloid proteins to form amyloid deposits, and a method of delivering a therapeutic agent to amyloid deposits. | 05-14-2009 |
20090136419 | HIGH DOSE RADIONUCLIDE COMPLEXES FOR BONE MARROW TREATMENT - The present invention relates to a method of suppressing bone marrow (BM) and treating conditions that arise in or near bone such as cancer, myeloproliferative diseases, autoimmune diseases, infectious diseases, metabolic diseases or genetic diseases, with compositions having as their active ingredient a radionuclide complexed with a chelating agent such as macrocyclic aminophosphonic acid. | 05-28-2009 |
20090155168 | IN VIVO IMAGING COMPOUNDS - The invention relates to a compound of formula (I) having use for in vivo imaging of the NR2B subtype of the NMDA receptor. | 06-18-2009 |
20090162280 | DETECTING SOLUBLE A-BETA - Agents, methods, and kits for qualitatively or quantitatively determining the presence of soluble A-beta in source of A-beta are provided, wherein the agents comprise the compound of formula III or the compound of formula III labeled with a signal generator. | 06-25-2009 |
20090169472 | METHODS AND COMPOSITIONS FOR TREATING IMMUNE DISORDERS - The present invention provides oligonucleotides, compositions comprising them and methods that use the oligonucleotides and compositions for stimulating cells expressing the TLR7 and/or TLR8 receptor. The oligonucleotides comprise for stimulating TLR7 comprise uracil-rich regions. The oligonucleotides for stimulating TLR8 comprise guanine-rich regions. The present methods and compositions are useful, inter alia, for treating or preventing conditions such as infectious disease and cancer. | 07-02-2009 |
20090180951 | INHIBITORS OF INTEGRIN VLA-4 - A complex, its stereoisomer or pharmaceutically acceptable salt has the formula I, where: | 07-16-2009 |
20090202435 | Diagnostic compounds for targeting a chemokine receptors - The present invention relates to a compound comprising, firstly a component for targeting at least one chemokine receptor and, secondly, a detection component capable of being identified by a medical imaging method. | 08-13-2009 |
20090202436 | Bupivacaine Formulation in a Polyorthoester Carrier - Effective treatments of pain, such as chronic pelvic pain, for extended periods of time are provided. The treatments include the administration of one or more drug depots intraspinally wherein the drug depots include an effective amount of bupivacaine formulated within a polyorthoester. By administration of one or more drug depots, one can relieve pain caused by diverse sources, including but not limited to chronic pelvic pain syndromes, spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discongenic back pain and joint pain, as well as pain that is incidental to surgery. In some embodiments, the relief can be for at least thirty days, at least sixty days, at least one hundred days or at least one hundred and thirty-five days. | 08-13-2009 |
20090220418 | MULTIMODAL IMAGING USING A THREE COMPARTMENT POLYMER NANOPARTICLE WITH CELL SPECIFICITY - The present invention pertains to a three compartment structured polymer nanoparticle (core-shell-corona) for multimodal imaging with specificity for cells or cellular components, thus enabling more advanced diagnostic approaches and targeted therapy on the cellular level without the use of additional biologically active materials. | 09-03-2009 |
20090238756 | IMAGE-GUIDED THERAPY OF MYOCARDIAL DISEASE: COMPOSITION, MANUFACTURING AND APPLICATIONS - Compositions and methods for imaging and for chemotherapy and radiotherapy are disclosed. More particularly, the invention concerns agents comprising a targeting moeity comprising a beta-adrenergic receptor targeting compound conjugated or embedded with ethylenediamine. The present invention also concerns methods of application of such agents for imaging and treatment of cardiovascular diseases, and kits for preparing a radiolabeled therapeutic or diagnostic agent. | 09-24-2009 |
20090238757 | Methods and Compositions for Administering Therapeutic and Diagnostic Agents - Methods and compositions are described for targeting therapeutic and diagnostic molecules to particular types of cells using targeting antibodies or other targeting moeities. | 09-24-2009 |
20090238758 | RANDOM AND NON-RANDOM ALKYLENE OXIDE POLYMER ALLOY COMPOSITIONS - A polymeric material comprised of (i) at least one random copolymer comprised of ethylene oxide and one or more other alkylene oxide(s) and (ii) at least one non-random polymer comprised of one or more poly(alkylene oxide)s has been discovered. Preferably, it is a polymer alloy. Alkylene oxide homopolymers or block copolymers may be the non-random polymer. In a related discovery, an adhesive material can be made by suspending (a) particles in (b) a matrix of at least one poly(ethylene oxide) copolymer of ethylene oxide and propylene oxide, or a combination thereof. The handling characteristics may be adjusted for different utilities (e.g., from runny oil to hard wax). Applications include use as adhesive, cohesive, filler, lubricant, surfactant, or any combination thereof. In particular, the hard materials may be used for cleaning or waxing. | 09-24-2009 |
20090252674 | Tripodal Ligands with the Coordinating Motifs K2 -BH2 or K3 -BH3 Relevant for Biomedical Applications of Organometallic Complexes - The present invention relates to a compound for use as a chelator in the radioactive labeling of biomolecules with metal tricarbonyl complexes, which compound has the general Formula (I) wherein M is a monovalent cation, such as Li, Na, K, Tl, Rb, Cs or an alkyl ammonium; R1 is H, alkyl, aryl or a biomolecule; R2 is H or a pendant arm, said pendant arm optionally comprises a biomolecule, with the proviso that when R1 is H, R2 is not H or COOH, and when R1 is alkyl or aryl, R2 is not H. | 10-08-2009 |
20090252676 | N-ALKOXYAMIDE CONJUGATES AS IMAGING AGENTS - The present disclosure is directed to compounds, diagnostic agents, and related methods. In some cases, methods for treating patients are provided. More specifically, the disclosure provides compounds, diagnostic agents, and kits for detecting and/or imaging and/or monitoring elastin rich tissues. In addition, the disclosure provides methods of detecting and/or imaging and/or monitoring the presence of coronary plaque, carotid plaque, iliac/femoral plaque, aortic plaque, renal artery plaque, plaque of any arterial vessel, aneurism, vasculitis, other diseases of the arterial wall, and/or damage or structural changes in ligaments, uterus, lungs or skin, as indicated by changes in total vessel wall area, internal lumen size, and exterior arterial perimeter. | 10-08-2009 |
20090252677 | Probes for In Vivo Targeting of Active Cysteine Proteases - Activity-based probes, which are specific for certain active cysteine proteases (caspase, cathepsin and legumain) and carry radioactive labels, are disclosed. The present probes comprise an acyloxymethyketone (AOMK) “warhead” that binds only to active enzyme. The probes further comprise peptide-like structure that targets the probe to a specific cysteine protease or protease family, and a radiolabel on the probe, which is bound to the targeted enzyme. It has been found that the present probes are stable in vivo and give specific target images distinguishable over background. The preferred probes are labeled with a positron-emitting agent such as | 10-08-2009 |
20090274621 | USE OF PYRENE TO CARRY NON-PEPTIDE AGENTS ACROSS THE BLOOD BRAIN BARRIER - Described are methods for delivering a non-peptide agent across the blood-brain barrier, comprising administering to a subject a conjugate comprising (i) a non-peptide agent and (ii) pyrene, and related detection and therapeutic method. | 11-05-2009 |
20090274622 | NECROSIS AVID TRACER AGENT - The invention relates to a method for obtaining an image of ischemic, infarcted or necrotic tissue in a subject, comprising the step of administering an imaging agent comprising a phenanthro[1,10,9,8-opqra]perylene-7,14-dione compound. For example, the invention concerns to the use of phenanthro[1,10,9,8-opqra]perylene-7,14-dione derivatives, and more specifically hypericin or its derivatives, as necrosis or infarct specific agents. The phenanthro[1,10,9,8-opqra]perylene-7,14-dione derivatives can be labeled with a radionuclide, a radiopaque material or a material enhancing the effects magnetic resonance imaging. The invention further features a pharmaceutical composition comprising a phenanthro[1,10,9,8-opqra]perylene-7,14-dione compound optionally conjugated to a radionuclide or a radiopaque material, provided that said phenanthro[1,10,9,8-opqra]perylene-7,14-dione compound is not mono-[ | 11-05-2009 |
20090297443 | Labeled ALPHA4BETA2 Ligands and Methods Therefor - Contemplated compositions and methods are employed to bind in vitro and in vivo to an α4β2 nicotinic acetylcholine receptor in a highly selective manner. Where such compounds are labeled, compositions and methods employing such compounds can be used for PET and SPECT analysis. Alternatively, and/or additionally contemplated compounds can be used as antagonists, partial agonists or agonists in the treatment of diseases or conditions associated with α4ββ2 dysfunction. | 12-03-2009 |
20090304583 | PATHOLOGICAL TISSUE DETECTION AND TREATMENT EMPLOYING TARGETED BENZOINDOLE OPTICAL AGENTS - Novel tumor specific phototherapeutic and photodiagnostic agents are disclosed. The compounds consist of a carbocyanine dye for visualization, photosensitizer for photodynamic treatment, and tumor receptor-avid peptide for site-specific delivery of the probe and phototoxic agent to diseased tissues. A combination of these elements takes full advantage of the unique and efficient properties of each component for an effective patient care management. | 12-10-2009 |
20090304584 | CONJUGATES COMPRISING A GABA- OR GLYCINE COMPOUND, PHARMACEUTICAL COMPOSITIONS AND COMBINATIONS THEREOF AND THEIR USE IN TREATING CNS DISORDERS - Conjugates of a gamma-aminobutyric acid (GABA) compound or a glycine compound and an analgesic drug are disclosed. Further disclosed are pharmaceutical compositions containing these conjugates and uses thereof in the treatment of CNS-associated diseases or disorders, optionally in combination with a psychotropic drug. | 12-10-2009 |
20090311176 | 2-Arylpyrazolo[L,5-Alpha] Pyrimidin-3-YL Acetamide Derivatives as Ligands for Translocator Protein (18 Kda) - The invention provides compounds of formula (I) radiolabelled with | 12-17-2009 |
20090324494 | MAGNETIC NANO-COMPOSITE FOR CONTRAST AGENT, INTELLIGENT CONTRAST AGENT, DRUG DELIVERY AGENT FOR SIMULTANEOUS DIAGNOSIS AND TREATMENT, AND SEPARATION AGENT FOR TARGET SUBSTANCE - The present invention relates to water soluble magnetic nanocomposite using an amphiphilic compound. Specifically, the present invention relates to water soluble magnetic nanocomposite which may be not only used as a contrast agent for magnetic resonance imaging (MRI), an intelligent contrast agent for diagnosing cancer characterized by binding a tissue-specific binder ingredient, a drug delivery system for simultaneous diagnosis and treatment by polymerizing or enveloping drugs and binding a tissue-specific binder ingredient, but also used for separating a target substance using magnetism, and a process for preparing the same. | 12-31-2009 |
20090324495 | COMPOUNDS AND METHODS FOR ENZYME-MEDIATED TUMOR IMAGING AND THERAPY - The invention provides methods and compositions, e.g., for tumor imaging and therapy. | 12-31-2009 |
20100003190 | Method for protecting renal tubular epithelial cells from radiocontrast nephropathy (RCN) - According to aspects of the invention, methods for preventing or treating kidney damage are provided. Compositions for the prevention or treatment of kidney damage are also provided. Aspects of the invention relate to methods for screening the toxicity of a radio-contrast agent. Kits for the treatment or prevention of kidney damage are also provided. | 01-07-2010 |
20100003191 | AURONE DERIVATIVE-CONTAINING COMPOSITION FOR DIAGNOSIS - The present invention provides a composition for diagnosing amyloid-related diseases, comprising a compound represented by general formula (I): | 01-07-2010 |
20100015049 | METHODS AND COMPOSITIONS FOR TREATING POSTOPERATIVE PAIN COMPRISING NONSTEROIDAL ANTI-INFLAMMATORY AGENTS - Methods and compositions are provided for reducing, treating or preventing postoperative pain and/or inflammation in a patient in need of such treatment, the methods and compositions comprising administering one or more biodegradable drug depots comprising a therapeutically effective amount of diclofenac and/or ketoprofen or pharmaceutically acceptable salt thereof to a target tissue site, wherein the drug depot releases an effective amount of diclofenac and/or ketoprofen or pharmaceutically acceptable salt thereof over a period of 3 to 15 days. | 01-21-2010 |
20100015050 | PEG AND TARGETING LIGANDS ON NANOPARTICLE SURFACE - Provided are compositions of nanoparticles, PEG and targeting moieties. The compositions are useful in treating tumors, imaging the particles in tissues, and in targeting therapeutic agents to specific tissues and locations in a patient. Also provided are methods of preparing and methods of using the compositions. | 01-21-2010 |
20100021380 | DIEGHYLENETRIAMINEPENTAACETIC ACID (DTPA)-MODIFIED FERROFLUID, PREPARATION METHOD OF THE SAME AND USES OF THE SAME IN PREPARATION OF PEPTIDE FERROFLUID - A present invention relate to a diethylenetriaminepentaacetic acid (DTPA)-modified ferrofluid and a preparation method of the same. The DTPA-ferrofluid contains DTPA and a nano ferrofluid. The DTPA-ferrofluid can be further mixed with a peptide. Unmodified or modified peptide ferrofluids prepared from the DTPA-modified ferrofluid, such as unmodified or modified octreotide-containing or unmodified or modified lanreotide-containing ferrofluid. | 01-28-2010 |
20100061928 | LABELLED ANALOGUES OF HALOBENZAMIDES AS RADIOPHARMACEUTICALS - The present invention relates to the use of a compound of formula (I): | 03-11-2010 |
20100068138 | STRUCTURALLY RIGID DOPAMINE D3 RECEPTOR SELECTIVE LIGANDS AND PROCESS FOR MAKING THEM - A family of structurally rigid dopamine D3 receptor selective ligands is described. The family of structurally rigid dopamine D3 receptor selective ligands has the formula wherein A is cis or trans —CH═CH—, —C═C—, or cyclohexyl. B is cis or trans —CH═CH— or absent. R1 represents an optionally substituted phenyl group, wherein said substituents are selected from the group consisting of: hydrogen, halogen, amino, nitro, hydroxyl, alkoxy, alkyl, acyl and pyridyl, and said substitution may occur at any of the ortho, meta, or para positions, or R1 represents a heteroaromatic ring. A preferred heteroaromatic ring is indole, quinoxoline, pyridyl, pyrimidyl, or imidazole. R2 and R3 may be independently hydrogen or a halogen, or R2 alone may be C1, C2, or C3 alkoxy, and m is 1 or 2, and n is 0, 1, or 2. | 03-18-2010 |
20100074842 | Technetium-99m (I) Tricarbonyl Complexes with Tridentate Chelators for Myocardium Imaging - Chelators of the formulae (I), (II) and (III) and tricarbonyl complexes of radioisotopes of Tc and Re bound to them, for use in myocardial imaging. | 03-25-2010 |
20100092385 | Novel Heteroaryl Substituted Imidazo [1,2-A] Pyridine Derivatives - The present invention relates to novel heteroaryl substituted imidazopyridine derivatives, precursors thereof, and therapeutic uses of such compounds, having the structural formula (Ia) and to their pharmaceutically acceptable salt, compositions and methods of use. Furthermore, the invention relates to novel heteroaryl substituted imidazopyridine derivatives that are suitable for imaging amyloid deposits in living patients, their compositions, methods of use and processes to make such compounds. More specifically, the present invention relates to a method of imaging amyloid deposits in brain in vivo to allow antemortem diagnosis of Alzheimer's disease as well as measuring clinical efficacy of Alzheimer's disease therapeutic agents. | 04-15-2010 |
20100098629 | Novel Amides Acting on the Adenosine Receptors - There are described Compounds of formula (I) in which R | 04-22-2010 |
20100098630 | Phenazine and Quinoxaline Substituted Amino Acids and Polypeptides - Disclosed herein are non-natural amino acids and polypeptides that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The non-natural amino acids, by themselves or as a part of a polypeptide, can include a phenazine or quinoxaline substituent. Also disclosed herein are non-natural amino acid polypeptides that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such polypeptides. | 04-22-2010 |
20100098631 | Novel-2-Heteroaryl Substituted Indoles 695 - The present invention relates to novel 2-heteroaryl substituted indole derivatives, precursors thereof, and therapeutic uses of such compounds, having the structural formula (Ia) below: and to their pharmaceutically acceptable salt, compositions and methods of use. Furthermore, the invention relates to novel 2-heteroaryl substituted indole derivatives that are suitable for imaging amyloid deposits in living patients, their compositions, methods of use and processes to make such compounds. More specifically, the present invention relates to a method of imaging amyloid deposits in brain in vivo to allow antemortem diagnosis of Alzheimer's disease as well as measuring clinical efficacy of Alzheimer?s disease therapeutic agents. | 04-22-2010 |
20100104512 | Dendritic Chelated Compounds, Methods for Making the Same and Pharmaceutical Compositions Containing the Same - The invention relates to dendritic chelated compounds, to methods for producing the same and to pharmaceutical compositions containing the same. The dendritic chelated complexes of the present invention have the following formula (I): [[MC]E | 04-29-2010 |
20100111858 | Diangostic and Therapeutic Cyclooxygenase-2 Binding Ligands - The present invention provides conjugates useful for the diagnosis and treatment of diseases associated with the over-expression of COX-2. The conjugates comprise a selective COX-2 targeting carrier, a metal coordinating moiety, and a linker chemically linking the metal coordinating moiety to the carrier. The metals coordinated by the metal coordinating moiety are selected from paramagnetic or radioisotopes. The invention also includes kits comprising a conjugate and a radioisotope solution. | 05-06-2010 |
20100111859 | Visualization of Biological Material by the Use of Coated Contrast Agents - A method for visualizing biological material, preferably by MRI, comprising the steps of: (i) bringing a population of coated nanoparticles into contact with said biological material, each of which nanoparticles comprises a) a metal oxide of a transition metal, said metal oxide preferably being paramagnetic and preferably comprising a lanthanide (+III) such as gadolinium (+III), and b) a coating covering the surface of the core particle, and (ii) recording the image; wherein the coating is hydrophilic and comprises a silane layer which is located next to the surface of the core particle and comprises one or more different silane groups which each comprises an organic group R and a silane-siloxane linkage where a) R comprises a hydrophilic organic group R′ and a hydrophobic spacer B, b) O is oxygen directly binding to a surface metal ion of the metal oxide, and c) C is carbon and is also part of B. A composition for visualization and methods for the manufacture of the nanoparticles and core particles are also disclosed. Visualization includes imaging by MR, CT, X-ray, near IR fluorescence, PET, microscopying etc with the largest advantages accomplished for in-vivo imaging. | 05-06-2010 |
20100143248 | METHODS FOR DIAGNOSING AND MONITORING TREATMENT OF ADHD BY ASSESSING THE DOPAMINE TRANSPORTER LEVEL - A method of diagnosing attention deficient-hyperactivity disorder (ADHD) in a human patient by assessing the level of dopamine transporter in at least one region of the patient's central nervous system, where an elevated level of dopamine transporter in the patient is indicative of ADHD. In embodiments of the invention, assessment of dopamine transporter levels includes assessing binding of a dopamine transporter ligand to the dopamine transporters using PET or SPECT. | 06-10-2010 |
20100143249 | FOLATE-CONJUGATES AND CORRESPONDING METAL-CHELATE COMPLEXES FOR USE IN DIAGNOSTIC IMAGING AND RADIOTHERAPY - The present invention is directed towards novel folate-conjugates of formula I | 06-10-2010 |
20100150831 | MODULATORS OF CXCR7 - Compounds having formula I, | 06-17-2010 |
20100150832 | BIODEGRADABLE POLYKETAL POLYMERS AND METHODS FOR THEIR FORMATION AND USE - The present invention relates to biodegradable biocompatible polyketals, methods for their preparation, and methods for treating animals by administration of biodegradable biocompatible polyketals. In one aspect, a method for forming the biodegradable biocompatible polyketals comprises combining a glycol-specific oxidizing agent with a polysaccharide to form an aldehyde intermediate, which is combined with a reducing agent to form the biodegradable biocompatible polyketal. The resultant biodegradable biocompatible polyketals can be chemically modified to incorporate additional hydrophilic moieties. A method for treating animals includes the administration of the biodegradable biocompatible polyketal in which biologically active compounds or diagnostic labels can be disposed. The present invention also relates to chiral polyketals, methods for their preparation, and methods for use in chromatographic applications, specifically in chiral separations. A method for forming the chiral polyketals comprises combining a glycol-specific oxidizing agent with a polysaccharide to form an aldehyde intermediate, which is combined with a suitable reagent to form the chiral polyketal. A method for use in chiral separations includes the incorporation of the chiral polyketals in the mobile phase during a chromatographic separation, or into chiral stationary phases such as gels. The present invention further relates to chiral polyketals as a source for chiral compounds, and methods for generating such chiral compounds. | 06-17-2010 |
20100150833 | COMPOUNDS AND AMYLOID PROBES THEREOF FOR THERAPEUTIC AND IMAGING USES - The present invention provides compounds and amyloid probes thereof that allow for an antemortem method of diagnosing AD and quantitating the extent or progression of amyloid deposits (plaques) by in vivo imaging of amyloid and/or amyloid deposits in the regions of the brain. Preferably, an amyloid probe of the invention can cross the blood-brain barrier and distinguish AD brain from normal brain. An amyloid probe can be administered to a patient in amounts suitable for in vivo imaging of amyloid deposits. Amyloid probes of the invention can also be used to detect and quantitate amyloid deposits in diseases including, without limitation, Down's syndrome, familial AD and homozygotes for the apolipoprotein E4 allele. In one aspect, the compounds may be used in the treatment or prophylaxis of diseases that include, without limitation, AD and type 2 diabetes mellitus. The compounds and amyloid probes of the invention include analogs, salts, pharmaceutical compositions, derivatives, prodrugs, racemic mixtures or tautomeric forms thereof. | 06-17-2010 |
20100172834 | METHOD FOR AUTOMATED, LARGE-SCALE MEASUREMENT OF THE MOLECULAR FLUX RATES OF THE PROTEOME OR THE ORGANEOME USING MASS SPECTROMETRY - Disclosed here is a method for measuring the kinetics (i.e., the molecular flux rates—synthesis and breakdown or removal rates) of a plurality of proteins or organic metabolites inn living systems. The methods may be accomplished in a high-throughput, large-scale automated manner, by using existing mass spectrometric profiling techniques and art well known in the fields of static proteomics and static organeomics, without the need for additional biochemical preparative steps or analytic/instrumental devices. | 07-08-2010 |
20100178246 | TECHNETIUM- AND RHENIUM-BIS(HETEROARYL) COMPLEXES AND METHODS OF USE THEREOF FOR INHIBITING PSMA - A compound of Formula I, a pharmaceutically acceptable salt, or solvate thereof: | 07-15-2010 |
20100178247 | CA-IX SPECIFIC RADIOPHARMACEUTICALS FOR THE TREATMENT AND IMAGING OF CANCER - A compound that recognizes and binds to the CA-IX protein has Formula I, II, III, or IV. The compounds may include a radioactive element for radioimaging or therapeutic applications. Thus, pharmaceutical compositions may be prepared with one or more of the compounds of Formula I, II, III, or IV. | 07-15-2010 |
20100183508 | RADIOACTIVE MIXTURE AND MANUFACTURING METHOD THEREOF - A radioactive mixture and a manufacturing method thereof are disclosed. The radioactive mixture ( | 07-22-2010 |
20100183509 | TECHNETIUM- AND RHENIUM-BIS(HETEROARYL) COMPLEXES AND METHODS OF USE THEREOF - Complexes of heterocyclic radionuclides are prepared based upon ligands having substituted pyridyl and imidazolyl groups. The ligands are bifunctional, having amino acid residues that may act as a linker to a bioactive molecule, and a tridentate chelator that may complex the radionuclide. The bioactive molecule may be a peptide or somatostatin. | 07-22-2010 |
20100189643 | DRUG DELIVERY WITH STIMULUS RESPONSIVE BIOPOLYMERS - The present invention provides conjugate compounds comprising (a) an active compound; (b) optionally, but in some embodiments preferably, an affinity binding agent; and (c) a block copolymer, the block copolymer comprising: (i) a first elastin-like polypeptide having a first Tt and (U) a second elastin-like polypeptide having a second Tt greater than the first Tt. Method for the targeted delivering of an active compound in vivo to a selected region within a subject with such agents are also described. | 07-29-2010 |
20100189644 | ARGINASE INHIBITORS AND METHODS OF USE - The present invention is directed to arginase inhibitor compounds of formula IA or formula IB: | 07-29-2010 |
20100196269 | SPIROCYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF THEIR USE - Spirocyclic heterocyclic derivatives, pharmaceutical compositions containing these compounds, and methods for their pharmaceutical use are disclosed. In certain embodiments, the spirocyclic heterocyclic derivatives are ligands of the δ-opioid receptor and may be useful, inter alia, for treating and/or preventing pain, anxiety, gastrointestinal disorders, and other δ-opioid receptor-mediated diseases, disorders, and/or conditions. | 08-05-2010 |
20100215574 | PROCESS FOR PRODUCING AN INJECTABLE MEDICAMENT PREPARATION - The invention relates to a method for producing injectable medicament preparations containing a therapeutically and/or diagnostically effective substance which is comprised of an active agent, of a spacer molecule and of at least one protein-binding molecule. After being brought into contact with the body, said therapeutically and/or diagnostically effective substance covalently bonds to the body fluid constituents or tissue constituents via the protein-binding molecule, thus providing a form of transport of the active agent that an be hydrolytically or enzymatically cleaved, according to pH, in the body while releasing the active agent. | 08-26-2010 |
20100239496 | Imaging agents for detecting neurological disorders - Imaging agents of formula (I) and methods for detecting neurological disorders comprising administering to a patient in need compounds of formula (I) capable of binding to tau proteins and β-amyloid peptides are presented herein. The invention also relates to methods of imaging Aβ and tau aggregates comprising introducing a detectable quantity of pharmaceutical formulation comprising a radiolabeled compound of formula (I) and detecting the labeled compound associated with amyloid deposits and/or tau proteins in a patient. These methods and compositions enable preclinical diagnosis and monitoring progression of AD and other neurological disorders. | 09-23-2010 |
20100247433 | Use of non-canonical amino acids as metabolic markers for rapidly-dividing cells - The invention provides methods, reagents and systems to preferentially mark fast-proliferating cells/tissues (such as cancer), by incorporating non-natural amino acids into proteins, preferably in vivo, using the endogenous protein synthesis machinery of an organism. The incorporated non-natural amino acids contain reactive groups for further chemical reagents, which may serve as a “handle” to for a number of uses, such as imaging of cancer cells, targeting drugs to preferentially kill cancer cells, and proteomic analysis in the context of large scale or high throughput screening for candidate drug leads that affects the proliferation of a target cell, etc. | 09-30-2010 |
20100254900 | Biocompatible polymers and Methods of use - Compositions and methods for manufacturing polymers are disclosed. Compositions include novel plastics, including films and shaped forms comprising polymer matrices that are biologically compatible and biodegradable. Such plastics may comprise polymers derived from natural sources. Further, such plastics are useful in biological systems for wound repair, implants, stents, drug encapsulation and delivery, and other applications. The disclosed methods comprise mild manufacturing processes such that various additives, such as biologically active proteins, sugars, lipids, and the like may be incorporated into the polymer matrix without subsequent loss of bioactivity during processing. Additionally, methods of manufacture for controlling mechanical properties, such as elasticity, pliancy, and the porosity of such plastics are disclosed. | 10-07-2010 |
20100260671 | COMPOUNDS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF AMYLOID ASSOCIATED DISEASES - The invention is in general directed to compounds, such as tannic acid, nicotine, nicotine derivatives and pyrrolid derivatives of nicotine, and methods for diagnosing, preventing or alleviating the symptoms of amyloid-associated diseases, for example, neuronal diseases, such as, for example, Alzheimer's disease, compounds and methods for inhibiting ion channel activity of beta amyloid, and methods of diagnostic imaging of A/3 fibrils. | 10-14-2010 |
20100272641 | LABELED MOLECULAR IMAGING AGENTS, METHODS OF MAKING AND METHODS OF USE - Imaging agents that comprise labeled substrates of the cystine/glutamate antiporter of cells, whereby the methods of use comprise introducing the labeled agents into cells via the cystine/glutamate antiporter, which are then reduced to a labeled cysteine, and subsequently detected in the cell. | 10-28-2010 |
20100272642 | PET PROBE HAVING AN ALKOXY GROUP SUBSTITUTED BY FLUORINE AND HYDROXY GROUP - Disclosed are: a PET probe compound having an alkoxy group substituted by a fluorine and a hydroxy group, which is useful for the early diagnosis of a conformational disease; a pharmaceutical composition for the treatment and/or prevention of a conformational disease, which comprises the compound; and others. | 10-28-2010 |
20100278730 | Non-Invasive Molecular Imaging of Cellular Histone Deacetylase Substrate Using Magnetic Resonance Spectroscopy (MRS) or Positron Emission Tomography (PET) - We disclose methods of detecting histone deacetylase activity in a mammal by administering to the mammal a compound comprising at least one atom having a nucleus detectable by magnetic resonance spectroscopy, wherein the compound is a substrate of histone deacetylase; and observing the compound or a cleavage product thereof in at least a portion of the body of the mammal by magnetic resonance spectroscopy (MRS). We also disclose methods of detecting histone deacetylase activity in a mammal by administering to the mammal a compound comprising at least one positron-emission-decaying radioisotope, wherein the compound is a substrate of histone deacetylase; and observing the compound or a cleavage product thereof in at least a portion of the body of the mammal by positron emission tomography (PET). We also disclose compounds useful as histone deacetylase substrates. | 11-04-2010 |
20100278731 | Mechanism-Based Targeted Pancreatic Beta Cell Imaging and Therapy - Compositions for imaging pancreatic beta cells comprise chelator-antidiabetic agent conjugates and optionally chelated metals. | 11-04-2010 |
20100284913 | Methods and compositions for studying, imaging, and treating pain - Saxitoxin analogue compounds, compositions, pharmaceutical compositions, methods of synthesis of saxitoxin analogues, methods of imaging, methods of treatment, including methods of treating pain, are provided. Saxitoxin (STX), gonyautoxin (GTX), and zetekitoxin, and variant STX compounds bind to sodium channels and are effective to reduce or block flow of sodium ions through such channels. Such channel block affects nerve and muscle action, and may be effective to reduce or block pain sensations, relax muscles, reduce muscle spasm, and reduce wrinkles. STX analogue binding to sodium channels may also be useful to locate, image, or mark sodium channels, and so be useful in studying sodium channels and sodium channel disorders, and in the diagnosis and treatment of patients suffering from sodium channel disorders. In embodiments, the variant STX compounds include conjugates having increased serum half-life as compared to STX when administered to a subject. | 11-11-2010 |
20100290986 | THERAPEUTIC USE OF DIAMINOPHENOTHIAZINES - The present invention relates generally to methods and materials for use in the treatment or prophylaxis of diseases, for example cognitive disorders, using diaminophenothiazines. In particular it relates to treatments having optimised pharmacokinetic properties, and dosage forms are intended to improve the relative cognitive or CNS benefits of the diaminophenothiazines, for instance compared to haematological effects. | 11-18-2010 |
20100297007 | LIGAND DIRECTED TOROIDAL NANOPARTICLES FOR THERAPY AND DIAGNOSTIC IMAGING - The present invention provides nanoparticles, methods of making the nanoparticles, and methods of using the nanoparticles to deliver therapeutic agents and/or imaging agents. | 11-25-2010 |
20100316566 | RADIOLABELED HEDGEHOG DERIVATIVES FOR IMAGING AND THERAPY - The present invention concerns methods and compositions related to a chelator and a HHRT ligand. In specific embodiments of the invention the chelator is conjugated to the HHRT ligand. In another specific embodiment of the invention, the chelator is chelated to a metal. In a particular embodiment of the invention, there is a metal species that is chelated to a chelator, which is then directly or indirectly conjugated to a HHRT ligand. In some embodiments, the composition further comprises a therapeutic agent. In particular cases, the compositions are employed for cancer diagnosis and/or therapy. | 12-16-2010 |
20100322854 | POSITRON EMISSION TOMOGRAPHY IMAGING METHOD - Described herein are compositions and methods for diagnosing and/or monitoring pathogenic disease states using positron emission tomography, wherein the pathogenic cells uniquely express, preferentially express, or overexpress vitamin receptors. Also described herein are | 12-23-2010 |
20100322855 | Bimodal ligands with macrocyclic and acyclic binding moieties, complexes and compositions thereof, and methods of using - Substituted 1,4,7-triazacyclononane-N,N′,N″-triacetic acid and 1,4,7,10-tetraazacyclcododecane-N,N′,N″,N′″-tetraacetic acid compounds with a pendant amino or hydroxyl group, metal complexes thereof, compositions thereof, and methods of making and use in diagnostic imaging and treatment of cellular disorders. | 12-23-2010 |
20100329978 | HIGHLY SELECTIVE SIGMA RECEPTOR LIGANDS - Compounds having the general formula II, III, or IV | 12-30-2010 |
20110002847 | METHOD OF FORMING AN INJECTABLE RADIOACTIVE COMPOSITION OF A CARBON ENCAPSULATED RADIOACTIVE PARTICULATE - A method of forming an injectable radioactive composition, the method comprising the steps of: (a) depositing a solid form of technetium onto a carbon crucible; (b) preheating the solid form of technetium to remove any carrier; (c) plasma ablating the technetium and portions of the carbon crucible; (d) allowing the carbon and technetium metal to co-condense from the gas phase to produce a nanoparticle composite aerosol in an inert gas; (e) dispersing the nanoparticle composite in water containing a low concentration of surfactant using an electrostatic precipitator; (f) size fractionating the nanoparticle dispersion by filtration with hydrophilic membranes of known pore size. | 01-06-2011 |
20110014121 | MODULATORS OF CXCR7 - Compounds having formula I, | 01-20-2011 |
20110033379 | RADIO-LABELED MATERIALS AND METHODS OF MAKING AND USING THE SAME - Radio-labeled materials, e.g., compounds and compositions, methods of making the radio-labeled materials, and applications of the same are disclosed. For example, novel solid-state methods are disclosed that produce radio-labeled compositions that include a reactive, but stable radio-labeled compound in a polar anhydrous solvent. The radio-labeled compounds can be readily conjugated with a variety of ligands. | 02-10-2011 |
20110038793 | MICROSPHERE COMPRISING AN ORGANIC LANTHANIDE METAL COMPLEX - The invention provides a microsphere comprising an organic lanthanide metal complex wherein the lanthanide metal is present in an amount of more than 20 wt %, based on total microsphere. The invention further provides a suspension comprising such a microsphere. In addition, the invention relates to a method for preparing said microsphere, and the use of the microsphere(s) or suspension for treating a malignancy and/or obtaining a scanning image. | 02-17-2011 |
20110052490 | ENDOSCOPIC MUCOSAL RESECTIONING USING PURIFIED INVERSE THERMOSENSITIVE POLYMERS - One aspect of the invention relates to use of a composition comprising a purified inverse thermosensitive polymer in an endoscopic procedure for gastrointestinal mucosal resectioning in a mammal. Another aspect of the invention relates to a method of gastrointestinal mucosal resectioning, comprising administering submucosally to a region of a gastrointestinal mucosa in a mammal an effective amount of a composition comprising a purified inverse thermosensitive polymer; and surgically resecting said region of gastrointestinal mucosa. Yet another aspect of the invention relates to a kit for use in gastrointestinal endoscopic mucosal resectioning in a mammal, comprising a composition comprising a purified inverse thermosensitive polymer; a syringe; and instructions for use thereof. | 03-03-2011 |
20110064656 | Methods of Determining Renal Function using Technetium-99m Tricarbonyl-nitrilotriacetic acid - This disclosure relates to the methods of imaging the kidneys and measuring renal function using the renal tracer | 03-17-2011 |
20110070157 | RADIOMETAL-LABELED AMINO ACID ANALOGS, IMAGING AND THERAPEUTIC AGENTS INCORPORATING THE SAME, AND METHODS USING THE SAME - An amino acid analog is provided, in syn-stereoisomeric form, anti-stereoisomeric form, or a combination thereof. The amino acid analog includes a cyclobutane ring with at least one of an amine group and a carboxyl group attached to one carbon node of the cyclobutane ring. A chain of moieties X, Y, and Z attached to one of remaining three carbon nodes of the cyclobutane ring. X is a chelating agent selected from a group comprising DCTA, DOTA, DTPA, EDTA, NOTA, PCTA, and TETA. Y is a linking moiety selected from a group comprising —NH—CO— and —NH-p-CHSN-Bn- where the linking moiety facilitates incorporation of the chelating agent into the amino acid analog. Z is a metal radioisotope selected from a group comprising Cu-60, Cu-61, Cu-62, Cu-64, Cu-67, Ga-67, Ga-68, Y-86, Y-88, Y-90, Sr-85, Sr-89, Gd-153, Gd-157, Sm-153, Lu-177, W-185, Re-186, Re-188, and Ir-192. | 03-24-2011 |
20110085974 | SMALL MOLECULE LIGAND-DRUG CONJUGATES FOR TARGETED CANCER THERAPY - The present invention describes small molecule ligand-drug conjugates and methods of using the small molecule ligand-drug conjugates for targeted treatment of cancer in a patient in need thereof. Further described are methods of sterilizing circulating tumor cells and determining drug concentration in cancer tissue. | 04-14-2011 |
20110097263 | KIT FORMULATION FOR THE PREPARATION OF IMMUNOLIPOSOME DRUG IN COMBINED BIMODALITY RADIOCHEMOTHERAPY - A kit formulation for the preparation of immunoliposome drug in combined chemotherapy and radionuclide therapy is disclosed, which consists: (1) a vial A containing proteins; (2) a vial B containing Traut's reagent; (3) a vial C containing DSPC, Cholesterol, mPEG-DSPE, Mal-DSPE-PEG and chemotherapy drug; (4) a vial D containing BMEDA, gluconate acetate, SnCl | 04-28-2011 |
20110104054 | Small-Molecule HSP90 Inhibitors - Hsp90 inhibitors having are provided having the formula: | 05-05-2011 |
20110104055 | SUBSTITUTED N-ARYL BENZAMIDES AND RELATED COMPOUNDS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES - Compounds and their pharmaceutically acceptable salts, their synthesis and labeling, pharmaceutical compositions containing them, and their use in the treatment of amyloid diseases, including Aβ amyloidosis, such as observed in Alzheimer's disease, IAPP amyloidosis, such as observed in type 2 diabetes, and synucleinopathies, such as observed in Parkinson's disease, and the manufacture of medicaments for such treatment are provided. Also provided is the use of the disclosed compounds as imaging agents and methods for in vivo imaging and detection of amyloid and synuclein. | 05-05-2011 |
20110104056 | NOVEL MOLECULAR ASSEMBLY, MOLECULAR PROBE FOR MOLECULAR IMAGING AND MOLECULAR PROBE FOR DRUG DELIVERY SYSTEM USING THE SAME, AND MOLECULAR IMAGING SYSTEM AND DRUG DELIVERY SYSTEM - The present invention provides a molecular assembly which is less likely to accumulate in tissue other than cancer tissue, is highly safe for a living body, and can be prepared by a simple and safe method and whose particle size can be easily controlled. The present invention provides a molecular imaging system and a molecular probe useful for the system, and a drug delivery system and a molecular probe useful for the system. The present invention provides a method for preparing molecular assembly, by which the particle size of molecular assembly having a signal group or a drug can be arbitrarily controlled in order to allow the molecular assembly to effectively accumulate in cancer tissue by utilizing EPR effect. A molecular assembly comprising: an amphiphilic block polymer A comprising a hydrophilic block chain and a hydrophobic block chain having 10 or more lactic acid units; a hydrophobic polymer A2 having at least 10 or more lactic acid units; and/or a labeled polymer B comprising at least 10 or more lactic acid units and a labeling group. | 05-05-2011 |
20110117014 | NON-INVASIVE DIAGNOSTIC AGENTS AND METHODS OF DIAGNOSING INFECTIOUS DISEASE - The present invention is directed to novel non-invasive diagnostic tools to diagnose numerous infectious disease states or conditions. The present invention represents a clear advance in the art which presently relies on tissue biopsy for diagnoses of these disease states. The novel imaging probe is capable of detecting infected cells, as well tissue. This represents a quanturn step forward in the diagnosis and staging of NHL using non-invasively molecular imaging techniques. This novel probe will also be useful to monitor patients response to therapeutic treatments and other interventions or therapies used in the treatment of these disease states or conditions. Compounds according to the present invention may be used as diagnostic tools for a number of conditions and diseases states as well as therapeutic agents for treating such conditions and disease states. Pharmaceutical compositions are also described. | 05-19-2011 |
20110117015 | Diagnostic Agents Selective Against Metalloproteases - The invention relates to aryl-sulphonamido compounds endowed with affinity against metallo proteases MMP, having formula (I) below wherein R, R | 05-19-2011 |
20110123446 | DEGRADABLE COMPOUNDS AND METHODS OF USE THEREOF, PARTICULARLY WITH PARTICLE REPLICATION IN NON-WETTING TEMPLATES - The present invention provides compounds that will degrade under specified conditions, methods of using such compounds, and compositions comprising such compounds. The degradable compounds of the invention may be characterized by the labile —Si-A-C— groups present in the compounds (A representing an atom, such as O, N, or S, or a group, such as C═O). The compounds may be incorporated into a composition that further may include a polymeric matrix and/or a cargo component. A wide variety of cargo components may also be used in the present invention. In particular embodiments, the cargo component comprises a drug or other therapeutic agent. Accordingly, the invention particularly provides pharmaceutical formulations and methods of delivering a drug or other therapeutic material. | 05-26-2011 |
20110135571 | HYBRID NANOPARTICLES AS ANTI-CANCER THERAPEUTIC AGENTS AND DUAL THERAPEUTIC/IMAGING CONTRAST AGENTS - The presently disclosed subject matter provides nanoscale coordination polymers for use as anticancer agents and as dual anticancer/imaging agents. The nanoscale coordination polymers can comprise a plurality of platinum metal complexes; nonplatinum anticancer drug bridging ligands complexed to multiple metal centers; or combinations thereof. The nanoscale coordination polymers can be targeted for delivery to cancer cells. They can also comprise stabilizing agents to allow for controlled and/or sustained release of anticancer agents in vivo. | 06-09-2011 |
20110165074 | CHELATING AMPHIPHILIC POLYMERS - Described are amphiphilic polymers that are provided with chelating moieties. The amphiphilic polymers are block copolymers comprising a hydrophilic block and a hydrophobic block, with the chelating moieties linked to the end-group of the hydrophilic block. The disclosed polymers are capable of self-assembly into structures such as micelles and polymersomes. With suitable metals present in the form of coordination complexes with 5 the chelating moieties, the chelating amphiphilic polymers of the invention are suitable for use in various imaging techniques requiring metal labeling, such as MRI (T | 07-07-2011 |
20110182810 | CENTRAL NERVOUS SYSTEM LABELLING COMPOSITION FOR INTRANASAL ADMINISTRATION AND LABELLING METHOD AND SCREENING METHOD USING CENTRAL NERVOUS SYSTEM LABELLING COMPOSITION FOR INTRANASAL ADMINISTRATION - There is provided a central nervous system labelling composition for intranasal administration for the purpose of labelling the central nervous system from the olfactory epithelium by way of the olfactory bulb and by means of intranasal administration. Additionally, there is provided a method of non-invasively labelling the central nervous system by way of an administration route that entails little transferability to the entire body. Furthermore, there is provided a screening method using a central nervous system labelling composition for intranasal administration. A central nervous system labelling composition for intranasal administration is characterized by labelling the central nervous system from the olfactory epithelium by way of the olfactory bulb and by means of intranasal administration and by containing at least one compound expressed either by the general formula (1) or the general formula (2) shown below as effective component: | 07-28-2011 |
20110206604 | NITROIMIDAZOLE-AMINO ACID HYPOXIA CONTRAST MEDIUM, PREPARATION METHOD AND USE THEREOF - A hypoxia contrast medium including nitroimidazole-amino acid chelate with a positively charged radioactive nuclide, a preparation method and use thereof. The contrast medium can be used in imaging cerebral thrombosis, tumors or other diseases such as ulceration, thrombosis, and so on. | 08-25-2011 |
20110236308 | Aryl Bidentate Isonitriles and Their Uses - The present invention relates generally to chelation compounds, radionuclide metal chelate compounds, i.e., complexes, and radiolabeled targeting moieties, i.e., conjugates, formed therefrom, and methods of using these compounds, complexes and conjugates for diagnostic and therapeutic purposes. This invention is more particularly related to aryl bidentate isonitrile metal complexes generated by a chemical interaction of a metal salt oxide or weak complex of the metal with aryl isonitrile bidentate ligands. | 09-29-2011 |
20110243843 | FLUORESCENT SILICA NANOPARTICLES FOR DETECTING LYMPH NODE AND THE IDENTIFICATION METHOD OF LYMPH NODE USING THEREOF - The present invention relates to fluorescent silica nanoparticles for detecting lymph node and identification method of lymph node using thereof. The functionalized silica nanoparticles containing fluorescent dye of this invention have a promising potential for sentinel node detection in the surgical field through fluorescent imaging. | 10-06-2011 |
20110243844 | SULFONAMIDE DERIVATIVE METABOTROPIC GLUTAMATE R4 LIGANDS - Disclosed are mGluR4 positive allosteric modulator ligands of general formula (I) and radiolabeled derivates, their use as therapeutic agents for the treatment of central nervous system disorders modulated by mGluR4 and as ligands for the labeling and diagnostic imaging of mGluR4 in mammals. | 10-06-2011 |
20110250132 | LIPOIC ACID METABOLITE: USEFUL FOR DRUG CARRIER, NANOPARTICLE CONJUGATE, IMAGING AND HYPERTHERMIA THERAPY - The present invention relates to simultaneous tracking or imaging followed by hyperthermia therapy for cancer and other diseases associated with altered metabolic enzymes. In particular, the invention relates to a novel class of therapeutic nanomaterial which selectively target and kill tumor cells. | 10-13-2011 |
20110262351 | FLUORESCENT SILICA NANOPARTICLE WITH RADIOACTIVE TAG AND THE DETECTING METHOD OF PET AND FLUORESCENT DUAL IMAGING USING THEREOF - The present invention relates to nuclear medicine using fluorescent silica nanoparticle and detecting method of optical dual imaging, and more particularly to radioisotope labeled fluorescent silica nanoparticles which are used for PET (positron emission tomography) and fluorescence detecting, and detecting method of PET and fluorescent dual imaging using thereof. Functionalized silica nanoparticles of this invention have promising potential as a role for organic lymphatic tracer in biomedical imaging such as pre- and intra-operative surgical guidance. | 10-27-2011 |
20110262352 | ARYL PIPERAZINE AND THEIR USE AS ALPHA2C ANTAGONISTS - Compounds of formula (I), wherein X, Z, A, B, D, E, R | 10-27-2011 |
20110286919 | CONJUGATES OF NOSCAPINE AND FOLIC ACID AND THEIR USE IN TREATING CANCER - The present invention is directed to compounds which are conjugates of two non-toxic natural products, noscapine (and various noscapine analogs) and folic acid (and various folic acid analogs), where the folic acid is conjugated to noscapine or the noscapine analog at the 9-position on the isoquinoline ring on the noscapine framework. Pharmaceutical compositions including the compounds, and methods of treating various tumors using the compounds and compositions, are also disclosed. The conjugates are particularly useful for treating cancers which overexpress the Folate Receptor α (FRa) receptor. | 11-24-2011 |
20110293515 | HETEROFUNCTIONAL SEGMENT-POLY (ETHYLENE GLYCOL) POLYMERS AS DELIVERY VEHICLES - Heterofunctional segment-poly(ethylene glycol) polymers, conjugates of these molecules with therapeutic and/or imaging agents, and methods for their use are disclosed. The heterofunctional segment-poly(ethylene glycol) polymers are useful as drug delivery conjugates, i.e., the heterofunctional segment-poly(ethylene glycol) polymers can be covalently attached to therapeutic agents (e.g., pharmaceutically active agents) and serve as delivery vehicles for the therapeutic agents. The heterofunctional segment-poly(ethylene glycol) polymers are also useful as imaging agent conjugates, i.e. the heterofunctional segment-poly(ethylene glycol) polymers can be covalently attached to imaging agents (e.g., tracers, imaging atoms, and imaging molecules) and serve as delivery vehicles for the imaging agents. Also disclosed are methods for treating a subject by administering to the subject an effective amount of the polymers conjugated to a therapeutic agent, an imaging agent, or a mixture thereof. | 12-01-2011 |
20110305632 | PROCESS FOR THE PREPARATION OF ASYMMETRICAL BIS(THIOSEMICARBAZONES) - The present invention relates to a method of making asymmetrical bis(thiosemicarbazones), compounds useful as synthetic intermediates in the method, new bis(thiosemicarbazones) that can be readily accessed by use of the method and methods of treatment and imaging utilising some of the new bis(thiosemicarbazones). | 12-15-2011 |
20110311444 | IMAGING DIAGNOSTIC AGENT AND EXTRACORPOREAL DIAGNOSTIC AGENT FOR INCURABLE NEUROLOGICAL DISEASES - Disclosed are a curcumin derivative or a salt thereof, which contains a fluorine atom, represented by formula (I): | 12-22-2011 |
20110318266 | PHTHALIMIDE DERIVATIVE METABOTROPIC GLUTAMATE R4 LIGANDS - Disclosed are mGluR4 positive allosteric modulator ligands of general formula (I) and radiolabeled derivates, their use as therapeutic agents for the treatment of central nervous system disorders modulated by mGluR4 and as ligands for the labeling and diagnostic imaging of mGluR4 in mammals. | 12-29-2011 |
20120003151 | METHOD FOR EARLY IMAGING OF ATHEROSCLEROSIS - The invention relates to methods of detecting active atherosclerotic plaques associated with blood vessel walls wherein the plaques comprise activated macrophages having accessible binding sites for a ligand. In one embodiment, plaques that block from about 2% to about 60% of the lumen of a blood vessel can be detected. | 01-05-2012 |
20120070372 | NON-INVASIVE DIAGNOSTIC AGENTS OF CANCER AND METHODS OF DIAGNOSING CANCER, ESPECIALLY LEUKEMIA AND LYMPHOMA - The present invention is directed to novel non-invasive diagnostic tools to image cancers, especially, leukemia and non-Hodgkin's lymphomas (NHL) with minimal toxicity in vivo. The present invention represents a clear advance in the art which presently relies on tissue biopsy for diagnoses of these cancers. The novel imaging probe is capable of detecting precancerous cells, as well as their metastatic spread in tissues. This represents a quantum step forward in the diagnosis and staging of NHL using non-invasively molecular imaging techniques. This novel probe will also be useful to monitor patients response to chemotherapy treatments and other interventions or therapies used in the treatment of NHL. Compounds according to the present invention may be used as diagnostic tools for a number of conditions and diseases states as well as therapeutic agents for treating such conditions and disease states. | 03-22-2012 |
20120093720 | Molecularly Imprinted Polymers for Use as Imaging and Therapeutics Agents - The invention described herein provides biocompatible molecularly imprinted polymers (MIPs) that are non-toxic, water soluble, small molecular weight, and degradable in a living body. The MIPs are capable of binding to all or a portion of a specific target macromolecule associated with a disease located within the living body and they are derivatized for stealth for in vivo applications to avoid the reticuloendothelial system. The MIPs of the invention are functionalized to an amine or carboxyl group and are derivatized with an imaging and/or therapeutic agent for taking images of the disease and/or for providing therapy. The macromolecule can be selected from a group consisting of proteins, glycoproteins, lipoproteins, peptidoglycans, peptides, polypeptides, polynucleotides, and polysaccharides. The invention described herein also provides methods and kits wherein MIPs of the invention can be employed as targeted imaging and therapeutic agents. | 04-19-2012 |
20120107236 | LIVER- RECEPTOR IMAGING INJECTION, DISPENSING METHOD AND PHARMACEUTICAL COMPOSITION THEREOF - The present invention is related to a pharmaceutical composition for a liver-receptor imaging injection, the pharmaceutical composition including a bi-functional compound which has a ASGPR specificity, wherein the bi-functional compound includes a backbone of alpha-amino acid (or the derivatives thereof) and a poly-galactosamine chain (or a poly-lactose chain) connected to the alpha-amino acid. Thereby, the pharmaceutical composition can quantify potential of liver storage ability and evaluate severity of the course of liver disease. A liver-receptor imaging injection using the same and the one-step dispensing method thereof are also provided to improve defects of iodine-labeled and overcome disadvantages of the reduced labeling-yield and the instability after autoclave sterilization. | 05-03-2012 |
20120128585 | Method of Diagnosing the presence of a tumor in a mammal by assessing CDO expression level - The present invention provides for a method of using BOC/CDO hedgehog antagonists to inhibit hedgehog signaling, as well as treating and diagnosing disorders relating to hedgehog signaling or overexpression of hedgehog, including cancer, cell proliferative disorders, and angiogenesis, neurological disorders, as well as other conditions affected by hedgehog signaling such as hair growth, neural stem cell differentiation, chondrogenesis and osteogenesis, lung surfactant production, formation of lamellated bodies in lung cells. | 05-24-2012 |
20120128586 | METHOD FOR TREATING CHRONIC LYMPHOCYTIC LEUKEMIA - The present invention provides a method for treating a subject having chronic lymphocytic leukemia (CLL) comprising administering to the subject one or more agents that target cell surface membrane antigens expressed preferentially on cells of the proliferative compartment of a CLL clone of the subject to treat chronic lymphocytic leukemia in the subject. The present invention also provides a method for treating a subject having chronic lymphocytic leukemia comprising administering to the subject one or more agents that target cell surface membrane antigens expressed preferentially on cells of the “resting re-entry compartment” to treat chronic lymphocytic leukemia in the subject. | 05-24-2012 |
20120148491 | METHOD OF OVERCOMING THERAPEUTIC LIMITATIONS OF NONUNIFORM DISTRIBUTION OF RADIOPHARMACEUTICALS AND CHEMOTHERAPY DRUGS - Disclosed is a method for predicting the optimal amounts of radiopharmaceutical and/or chemotherapy agents to administer to a patient, by determining the level of saturation of the therapeutic agents in the patient's cells. The method comprises measuring cellular incorporation of the candidate therapeutic agents in a target cell population on a cell-by-cell basis. The method is able to identify an optimal cocktail of therapeutic agents for treatment of a disease. A method of high-throughput drug discovery incorporating this method, and a 2-stage targeting method of treating a disease using this method are also disclosed. | 06-14-2012 |
20120164070 | BENZOTHIAZOLE AND BENZOOXAZOLE DERIVATIVES AND METHODS OF USE - Compounds of formula (I) | 06-28-2012 |
20120171116 | Arginase Inhibitors and Methods of Use Thereof - The present invention includes arginase enzyme inhibitors, compositions comprising these arginase inhibitors, and methods of treating or diagnosing conditions characterized either by abnormally high arginase activity or abnormally low nitric oxide levels in a mammal, comprising administering compositions of the invention to the mammal. | 07-05-2012 |
20120177569 | LABELLED BIOTIN CONJUGATES - The present invention provides radioactive gallium complexes which comprise DOTA-biotin conjugates, incorporating a linker group. Also described are radiopharmaceutical compositions, and methods and uses of the complexes for in vivo imaging involving pre-targeting with avidin. | 07-12-2012 |
20120177570 | TRPV1 ANTAGONISTS INCLUDING AMIDE SUBSTITUENT AND USES THEREOF - The invention relates to compounds of formula IA″ | 07-12-2012 |
20120189543 | Compositions and Methods for Detecting and Treating Implant Loosening and Osteolysis - Methods and compositions for detecting, diagnosing, and treating osteolysis and implant loosening are disclosed. | 07-26-2012 |
20120195832 | PROCESS FOR PRODUCING AN INJECTABLE MEDICAMENT PREPARATION - The invention relates to a method for producing injectable medicament preparations containing a therapeutically and/or diagnostically effective substance which is comprised of an active agent, of a spacer molecule and of at least one protein-binding molecule. After being brought into contact with the body, said therapeutically and/or diagnostically effective substance covalently bonds to the body fluid constituents or tissue constituents via the protein-binding molecule, thus providing a form of transport of the active agent that an be hydrolytically or enzymatically cleaved, according to pH, in the body while releasing the active agent. | 08-02-2012 |
20120207674 | CANCER-IMAGING AGENT AND METHOD OF RADIOIMAGING USING THE SAME - The cancer-imaging agent and method of radioimaging relates to the use of a radioimaging agent for the imaging increased choline uptake to detect cancerous tissue. The radioimaging agent includes choline or a pharmaceutically acceptable salt thereof labeled with technetium-99m. Preferably, the radioimaging agent is [methyl]-choline chloride labeled with | 08-16-2012 |
20120219496 | GADOLINIUM-LINKED NANOCLUSTERS - The invention relates to nanocluster compositions and uses thereof. Specifically, the invention relates to gadolinium-linked nanocluster compositions and their use in diagnosis and prognosis of diseases. The nanocluster compositions of the invention are effective in enhancing the payload of a gadolinium and thereby increasing the longitudinal relaxivity of each particle in the cluster. | 08-30-2012 |
20120219497 | RANDOM ETHYLENE OXIDE AND NON-RANDOM ALKYLENE OXIDE(S) POLYMERS - A polymeric material comprised of (i) at least one random copolymer comprised of ethylene oxide and one or more other alkylene oxide(s) and (ii) at least one non-random polymer comprised of one or more poly(alkylene oxide)s has been discovered. Preferably, it is a polymer alloy. Alkylene oxide homo-polymers or block copolymers may be the non-random polymer. In a related discovery, an adhesive material can be made by suspending (a) particles in (b) a matrix of at least one poly(ethylene oxide) copolymer of ethylene oxide and propylene oxide, or a combination thereof. The handling characteristics may be adjusted for different utilities (e.g., from runny oil to hard wax). Applications include use as adhesive, cohesive, filler, lubricant, surfactant, or any combination thereof. In particular, the hard materials may be used for cleaning or waxing. | 08-30-2012 |
20120225015 | Method for predicting autism spectrum disorders by cannabinoid and cannabinoid receptor expression - The inventive method relates to a method for the determination of susceptibility or diagnosis of autism or autism spectrum disorders. Diagnosis or determination of susceptibility determinations are predicated on quantitative analysis of endocannibinoid levels or endocannibinoid receptor expression. | 09-06-2012 |
20120251443 | IMPLANTABLE CONTRAST AGENTS AND METHODS - The present disclosure provides compositions and methods based on implantable contrast agents that are useful for imaging tissue and organs. | 10-04-2012 |
20120269724 | COMPOSITIONS AND METHODS FOR IMAGING TISSUES, ORGANS AND TUMORS - The present invention relates to compounds and related technetium and rhenium complexes thereof which are suitable for imaging or therapeutic treatment of tissues, organs, or tumors. In another embodiment, the invention relates to methods of imaging tissues, organs, or tumors using radiolabeled metal complexes, particularly tissues, organs, or tumors which express certain receptors to which the compounds or complexes of the invention have an affinity. The present invention also relates to methods of treating cancer, particularly those cancer lines which express certain receptors to which the compounds or complexes of the invention have an affinity. In yet another embodiment, the present invention provides methods of imaging and/or inhibiting receptors or neuroreceptors using compounds or complexes of the invention which have an affinity for the receptor or neuroreceptor to be imaged and/or inhibited. | 10-25-2012 |
20120321558 | COMPOSITIONS OF HIGH SPECIFIC ACTIVITY SN-117M AND METHODS OF PREPARING THE SAME - Compositions of high specific activity | 12-20-2012 |
20120321559 | HEXAHYDRO-PYRROLO-ISOQUINOLINE COMPOUNDS - Certain hexahydro-pyrrolo-isoquinoline compounds are histamine H | 12-20-2012 |
20120328514 | N-ALKOXYAMIDE CONJUGATES AS IMAGING AGENTS - The present disclosure is directed to compounds, diagnostic agents, and related methods. In some cases, methods for treating patients are provided. More specifically, the disclosure provides compounds, diagnostic agents, and kits for detecting and/or imaging and/or monitoring elastin rich tissues. In addition, the disclosure provides methods of detecting and/or imaging and/or monitoring the presence of coronary plaque, carotid plaque, iliac/femoral plaque, aortic plaque, renal artery plaque, plaque of any arterial vessel, aneurism, vasculitis, other diseases of the arterial wall, and/or damage or structural changes in ligaments, uterus, lungs or skin, as indicated by changes in total vessel wall area, internal lumen size, and exterior arterial perimeter. | 12-27-2012 |
20130004419 | Carbonylporphyrins and Uses Thereof - The present invention is directed to low toxicity boronated compounds and methods for their use in the treatment, visualization, and diagnosis of tumors. More specifically, the present invention is directed to low toxicity carborane-containing porphyrin compounds with halide, amine, or nitro groups and methods for their use particularly in boron neutron capture therapy (BNCT), X-ray radiation therapy (XRT), and photodynamic therapy (PDT) for the treatment of tumors of the brain, head and neck, and surrounding tissue. The invention is also directed to using these carborane-containing porphyrin compounds in methods of tumor imaging and/or diagnosis such as MRI, SPECT, or PET. | 01-03-2013 |
20130017149 | PHARMACEUTICAL COMPOUNDS - Condensed tricyclic compounds having a condensed structure containing one phenyl and one pyrazole ring linked with each other by a central ring comprising from five to eight atoms, having affinity for the CB1 and/or CB2 receptors, with central nervous system and/or peripheral activity, of formula (I): | 01-17-2013 |
20130034494 | RADIOLABELED PROSTATE SPECIFIC MEMBRANE ANTIGEN INHIBITORS - Compounds according to Formula I and Formula II are potent inhibitors of PSMA activity: | 02-07-2013 |
20130064764 | Miniaturized 62Zn/62Cu Generator for High Concentration Clinical Delivery of 62Cu Kit Formulation for the Facile Preparation of Radiolabeled Cu-BIS(Thiosemicarbazone) Compounds - A new system accomplishes easy, interchangeable production of multiple PET radiopharmaceuticals through the use of a simplified eluant-only generator and a kit based synthesis technique employing lyophilized or freeze dried ligand. Thus, by simply switching the lyophilized ligand vial kit, any number of | 03-14-2013 |
20130095035 | POLYANIONIC MULTIVALENT MACROMOLECULES FOR INTRACELLULAR TARGETING OF PROLIFERATION AND PROTEIN SYNTHESIS - The present invention relates generally to methods and compositions for targeting of intracellular molecules involved in proliferation and protein synthesis of activated cells using polyanionic multivalent macromolecules. In particular aspect, multiple sulfate groups linked to polyol are specifically targeted to the cytoplasm and nucleus of proliferating and activated cells. The invention further comprises novel polyanionic macromolecular compounds and formulations. | 04-18-2013 |
20130101505 | Stable Activatable Particles as Radiotherapeutic Agents for the Treatment of Disease - The present invention provides radiotherapeutic agents and compositions and methods for making and using the same. In some embodiments, the radiotherapeutic agent is a nanoparticle comprising a radionuclide and a carrier moiety. In some embodiments, the radionuclide is produced by activating a stable activatable particle via neutron activation. | 04-25-2013 |
20130129620 | Tricarbonyl Complexes with Tridentate Chelators for Myocardium Imaging - Chelators of the formulae (I), (II) and (III) | 05-23-2013 |
20130171066 | POLYMERIC COMPLEMENTS TO A B-AMYLOID PEPTIDES - The present invention relates to the preparation and use of polymer complements to β-amyloid peptides (Aβ) for detecting soluble or aggregated Aβ in fluid samples or for treating a subject having a neurodegenerative disease. | 07-04-2013 |
20130171067 | TECHNETIUM-99m COMPLEX AS A TOOL FOR THE IN VIVO DIAGNOSIS OF CANCEROUS TUMOURS - The invention relates to a compound having formula (I), compositions containing same and preparation methods thereof. The invention also relates to a complex of the compound having formula (I) with technetium-99m and tricine, the use of this complex as a diagnostic probe, diagnostic compositions containing same and methods for preparing the complex and compositions containing same. | 07-04-2013 |
20130183236 | MMP-TARGETED THERAPEUTIC AND/OR DIAGNOSTIC NANOCARRIERS - The present invention provides targeted delivery compositions and methods of using the compositions for treating and diagnosing a disease state in a subject. | 07-18-2013 |
20130189185 | Boron-Based Dual Imaging Probes, Compositions and Methods for Rapid Aqueous F-18 Labeling, and Imaging Methods Using Same - A composition useful as a PET and/or fluorescence imaging probe a compound a compound of Formula I, including salts, hydrates and solvates thereof: | 07-25-2013 |
20130202529 | BENZTROPINE COMPOUNDS AND USES THEREOF - Disclosed are benztropine analogs having the formula (I) | 08-08-2013 |
20130209357 | MOLECULAR PROBES FOR IMAGING MYELIN - A molecular probe for use in the detection of myelin in a subject includes a compound having the general formula selected from the group consisting of: formula (I), and pharmaceutically acceptable salts thereof. | 08-15-2013 |
20130216477 | METAL COMPLEXES OF POLY(CARBOXYL)AMINE-CONTAINING LIGANDS HAVING AN AFFINITY FOR CARBONIC ANHYDRASE IX - The present invention is directed to CA IX inhibitors that conform to Formula I where the substituents X, A, B, D, E, E′ and G are as defined above. | 08-22-2013 |
20130216478 | Non-Invasive Diagnostic Agents of Cancer and Methods of Diagnosing Cancer, Especially Leukemia and Lymphoma - The present invention is directed to novel non-invasive diagnostic tools to image cancers, especially, leukemia and non-Hodgkin's lymphomas (NHL) with minimal toxicity in vivo. The present invention represents a clear advance in the art which presently relies on tissue biopsy for diagnoses of these cancers. The novel imaging probe is capable of detecting precancerous cells, as well as their metastatic spread in tissues. This represents a quantum step forward in the diagnosis and staging of NHL using non-invasively molecular imaging techniques. This novel probe will also be useful to monitor patients response to chemotherapy treatments and other interventions or therapies used in the treatment of NHL. Compounds according to the present invention may be used as diagnostic tools for a number of conditions and diseases states as well as therapeutic agents for treating such conditions and disease states. | 08-22-2013 |
20130295009 | METHOD OF TREATING INFLAMMATION - The present invention relates to the use of compounds of general formula (I) as ligands to the melanocortin receptors and/or for treatment of disorders in the melanocortin system: | 11-07-2013 |
20130302245 | IMAGE-GUIDED THERAPY OF MYOCARDIAL DISEASE: COMPOSITION, MANUFACTURING AND APPLICATIONS - Compositions and methods for imaging and for chemotherapy and radiotherapy are disclosed. More particularly, the invention concerns agents comprising a targeting moeity comprising a beta-adrenergic receptor targeting compound conjugated or embedded with ethylenediamine. The present invention also concerns methods of application of such agents for imaging and treatment of cardiovascular diseases, and kits for preparing a radiolabeled therapeutic or diagnostic agent. | 11-14-2013 |
20130309168 | BACTERIAL IMAGING AGENTS AND METHODS OF USING SAME - The invention provides a family of agents that target bacterial infection, which can be used as imaging agents or therapeutic agents. The agents can be used to image sites of bacterial infection as well as other physiological processes in a subject. | 11-21-2013 |
20130315822 | N-ALKOXYAMIDE CONJUGATES AS IMAGING AGENTS - The present disclosure is directed to compounds, diagnostic agents, and related methods. In some cases, methods for treating patients are provided. More specifically, the disclosure provides compounds, diagnostic agents, and kits for detecting and/or imaging and/or monitoring elastin rich tissues. In addition, the disclosure provides methods of detecting and/or imaging and/or monitoring the presence of coronary plaque, carotid plaque, iliac/femoral plaque, aortic plaque, renal artery plaque, plaque of any arterial vessel, aneurism, vasculitis, other diseases of the arterial wall, and/or damage or structural changes in ligaments, uterus, lungs or skin, as indicated by changes in total vessel wall area, internal lumen size, and exterior arterial perimeter. | 11-28-2013 |
20130323170 | PROSTHETIC GROUPS ATTACHED TO STANNYL POLYMER IN THE SYNTHESIS OF RADIOPHARMACEUTICALS - The present invention relates to compositions and methods for preparing radiopharmaceutical compounds in high chemical-purity and isotopic-purity. The present invention provides polymer-bound precursors to radiopharmaceutical compounds that can be converted to radiopharmaceutical compounds in one step. In a preferred embodiment, a radiopharmaceutical precursor is bound to a polymeric support via a prosthetic group comprising an alkenyl-tin bond. The radiopharmaceutical precursor is converted to a radiopharmaceutical compound in one step involving cleavage of the alkenyl-tin bond and incorporation of a radioisotope to form the radiopharmaceutical compound. Importantly, the polymeric support containing the toxic tin by-product can be easily removed from the radiopharmaceutical compound by filtration. The present invention can be used to install a large number of different radioisotopes. In a preferred embodiment, the radioisotope is | 12-05-2013 |
20130336887 | COMPOUNDS AND METHODS FOR ENZYME-MEDIATED TUMOR IMAGING AND THERAPY - The invention provides methods and compositions, e.g., for tumor imaging and therapy. | 12-19-2013 |
20130336888 | PSMA-TARGETED DENDRIMERS - A dendrimer conjugate according to Formula (I), or its pharmaceutically acceptable salt, or solvate thereof: and complexes of Formula I conjugates with metals radionuclides of elements such as rhenium, technetium, yttrium, lutetium and others to provide a complex for imaging tissues or for the radiotherapeutic treatment of cancer tissue. Such complexes are specific to PSMA protein and can therefore be used in imaging or treating cancer of the prostate and other tissue where the protein is expressed. | 12-19-2013 |
20140037541 | RADIOIMAGING METHODS USING TEBOROXIME AND THALLIUM - A method for imaging is providing, including administering a teboroxime species to an adult human subject, administering T1-201-thallous chloride to the subject performing a teboroxime species SPECT imaging procedure of the teboroxime species on a region of interest (ROI) of the subject, and, after administering the teboroxime species, performing a T1-201-thallous chloride SPECT imaging procedure of the T1-201-thallous chloride on the ROI. Administering the teboroxime species and the T1-201-thallous chloride and performing the teboroxime species and the T1-201-thallous chloride SPECT imaging procedures comprise administering the teboroxime species and the T1-201-thallous chloride and performing the teboroxime species and the T1-201-thallous chloride SPECT imaging procedures during a time period having a duration of no more than 30 minutes. Other embodiments are also described. | 02-06-2014 |
20140037542 | NOVEL THERANOSTIC PLATFORM FOR TARGETED CANCER THERAPY AND DRUG DELIVERY MONITORING - A compound that includes a quaterrylene dye moiety as core, and a dendrimeric shell. For example, the compound may comprise at least four dendronized polyamides covalently attached to a quaterrylene dye. Also disclosed is a compound, or a pharmaceutically acceptable salt or ester thereof, comprising A(G) | 02-06-2014 |
20140056809 | TREATMENT AND DIAGNOSIS OF MACROPHAGE MEDIATED DISEASE - The invention relates to a method of treating or monitoring/diagnosing a disease state mediated by activated macrophages. The method comprises the step of administering to a patient suffering from a macrophage mediated disease state an effective amount of a composition comprising a conjugate or complex of the general formula | 02-27-2014 |
20140065066 | IMAGING AND THERAPEUTIC METHOD USING MONOCYTES - The invention relates to a method of treating or diagnosing a disease state mediated by monocytes. The method utilizes a composition comprising a conjugate or complex of the general formula | 03-06-2014 |
20140065067 | RADIOPAQUE IODINATED PRODUCTS INTENDED FOR USE MEDICAL IMAGING AND THEIR METHODS - Iodinated amphiphilic compound of formula (I): | 03-06-2014 |
20140079631 | ANTI-INFLAMMATORY PARTICLES - Described herein are compositions and methods relating to particles comprising at least one component of a cellular-derived microparticle. Aspects of technology described herein relate to compositions and methods for treating inflammation, wounds, and pain. | 03-20-2014 |
20140086833 | NON-INVASIVE DIAGNOSTIC AGENTS AND METHODS OF DIAGNOSING INFECTIOUS DISEASE - The present invention is directed to novel non-invasive diagnostic tools to diagnose numerous infectious disease states or conditions. The present invention represents a clear advance in the art which presently relies on tissue biopsy for diagnoses of these disease states. The novel imaging probe is capable of detecting infected cells, as well tissue. This represents a quantum step forward in the diagnosis and staging of NHL using non-invasively molecular imaging techniques. This novel probe will also be useful to monitor patients response to therapeutic treatments and other interventions or therapies used in the treatment of these disease states or conditions. Compounds according to the present invention may be used as diagnostic tools for a number of conditions and diseases states as well as therapeutic agents for treating such conditions and disease states. Pharmaceutical compositions are also described. | 03-27-2014 |
20140086834 | NEW I-ARYLPIPERAZINIC LIGANDS OF 5-HT7 RECEPTOR AND USE THEREOF - The invention relates to a new class of compounds able to inhibit with high affinity and selectivity the 5-HT7 receptor. The invention also relates to the utilization of such compounds as medicaments useful in the treatment and prevention of 5-HT7 receptor relating disorders of the central nervous system. The invention also relates to the isotopically labeled compounds for use in vivo diagnosis or imaging of a 5-HT7 condition. | 03-27-2014 |
20140154178 | METHODS OF DETECTING MYELIN BASIC PROTEIN - A method and a kit for detecting myelin basic protein are provided. The method comprises administering an agent, which binds to myelin basic protein (MBP), to a subject at risk of or diagnosed with a myelin-associated neuropathy, and determining myelination by detecting the agent resided in the subject. The amount of the agent present in the subject is indicative of a myelin-associated neuropathy. A method of quantifying an amount of MBP present in a tissue sample is also provided, wherein the method comprises contacting the tissue sample with the same agent, detecting the agent present in the tissue sample; and quantifying an amount of the agent present in the tissue sample. | 06-05-2014 |
20140154179 | CXCR7 ANTAGONISTS - Compounds having formula I, | 06-05-2014 |
20140154180 | Pharmacophores for Amyloid Fibers Involved in Alzheimer's Disease - This invention relates, e.g., to a method for designing or selecting on a computer a candidate small molecule amyloid binder or inhibitor, comprising: a) docking test compounds to the binding site or binding surface determined from the three-dimensional structure of a co-crystal of a protofilament of an amyloid protein bound to a small molecule which is known to bind to the amyloid protein, and (b) selecting test compounds which exhibit an energy below that of the small molecule used to form the co-crystal made in a), as candidate amyloid binders. | 06-05-2014 |
20140186260 | RADIOPHARMACEUTICAL AND PHARMACEUTICAL KIT - A radiopharmaceutical comprising combination of a particular radioactive dithiosemicarbazone copper complex, and a chelating agent comprising a multidentate ligand having a maximum dentate number of 2 or more to 4 or less. | 07-03-2014 |
20140186261 | ANTI-TUMOR AGENT AND ANTI-TUMOR KIT - An anti-tumor agent comprising combination of a radioactive diacetyl-bis(N4-methylthiosemicarbazone) copper complex and a metabolic inhibitor. | 07-03-2014 |
20140193336 | IMAGING PROTOCOLS - Protocols for radioimaging an event or disorder are provided. An exemplary protocol comprises a method of radioimaging a myocardial perfusion, the method comprising in sequence:
| 07-10-2014 |
20140199239 | Compositions and Methods for in Vivo Imaging - The present disclosure provides lipid-probe compounds, and compositions comprising the compounds. A subject lipid-probe compound is useful for various imaging applications, which are also provided. | 07-17-2014 |
20140205537 | LRRK2 INHIBITORS - Provided herein are compounds that inhibit or partially inhibit the activity of leucine rich repeat kinases. Also provided herein are methods of treatment of CNS disorders comprising administration of inhibitors of leucine rich repeat kinases. | 07-24-2014 |
20140219915 | CRYPTATE COMPOUNDS - Disclosed herein is a method for coupling a first compound having the formula (I) with a second compound that contains a carbonyl group. Also disclosed herein are compounds that can be formed by this method, and uses for such compounds. | 08-07-2014 |
20140255306 | TRIAZINE BASED RADIOPHARMACEUTICALS AND RADIOIMAGING AGENTS - Compounds according to Formula I and Formula II are potent inhibitors of PSMA. | 09-11-2014 |
20140271465 | MATRIX METALLOPROTEASE (MMP) TARGETED AGENTS FOR IMAGING AND THERAPY - The present invention provides compound conjugates of matrix metalloprotease inhibitors and linked metal chelators which are useful for imaging solid tumors and treating and diagnosing certain types of diseases such as cancer. | 09-18-2014 |
20140271466 | HSPC-Sparing Treatments for RB-Positive Abnormal Cellular Proliferation - This invention is in the area of improved compounds for and methods of treating selected RB-positive cancers and other Rb-positive abnormal cellular proliferative disorders while minimizing the deleterious effects on healthy cells, for example healthy Hematopoietic Stem Cells and Progenitor Cells (HSPCs), associated with current treatment modalities. In one aspect, improved treatment of select RB-positive cancers is disclosed using specific compounds disclosed herein. In certain embodiments, the compounds described herein act as highly selective and, in certain embodiments, short, transiently-acting cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors when administered to subjects. | 09-18-2014 |
20140341804 | HOMOMULTIVALENT AND HETEROMULTIVALENT INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PMSA) AND USES THEREOF - The present invention provides bivalent and multivalent ligands with a view to improving the affinity and pharmacokinetic properties of a urea class of PSMA inhibitors. The compounds and their synthesis can be generalized to multivalent compounds of other target antigens. Because they present multiple copies of the pharmacophore, multivalent ligands can bind to receptors with high avidity and affinity, thereby serving as powerful inhibitors. The modular multivalent scaffolds of the present invention, in one or more embodiments, contains a lysine-based (α-, ε-)dialkyne residue for incorporating two or more antigen binding moieties, such as PSMA binding Lys-Glu urea moieties, exploiting click chemistry and one or more additional lysine residues for subsequent modification with an imaging and/or therapeutic nuclides or a cytotoxic ligands for tumor cell killing. | 11-20-2014 |
20140341805 | TECHNETIUM- AND RHENIUM-BIS(HETEROARYL) COMPLEXES AND METHODS OF USE THEREOF - A method of imaging a region in a subject includes administering to the subject a complex of a metal chelated to a compound, and obtaining an image of the region in the subject. | 11-20-2014 |
20140341806 | NON-INVASIVE DIAGNOSTIC AGENTS OF CANCER AND METHODS OF DIAGNOSING CANCER, ESPECIALLY LEUKEMIA AND LYMPHOMA - The present invention is directed to novel non-invasive diagnostic tools to image cancers, especially, leukemia and non-Hodgkin's lymphomas (NHL) with minimal toxicity in vivo. The present invention represents a clear advance in the art which presently relies on tissue biopsy for diagnoses of these cancers. The novel imaging probe is capable of detecting precancerous cells, as well as their metastatic spread in tissues. This represents a quantum step forward in the diagnosis and staging of NHL using non-invasively molecular imaging techniques. This novel probe will also be useful to monitor patients response to chemotherapy treatments and other interventions or therapies used in the treatment of NHL. Compounds according to the present invention may be used as diagnostic tools for a number of conditions and diseases states as well as therapeutic agents for treating such conditions and disease states. | 11-20-2014 |
20140348746 | 4,4-DISUBSTITUTED CYCLOHEXYL BRIDGED HEPTAMETHINE CYANINE DYES AND USES THEREOF - The invention relates to a family of compounds that comprise fluorescent cyanine dyes. The compounds are near infrared absorbing heptamethine cyanine dyes with a 4,4-disubstituted cyclohexyl ring as part of the polymethine chromophore. The compounds are generally hydrophilic and can be chemically linked to biomolecules, such as proteins, nucleic acids, and therapeutic small molecules. The compounds can be used for imaging in a variety of medical, biological and diagnostic applications. | 11-27-2014 |
20140356283 | Probes, Methods of Making Probes, and Methods of Use - Embodiments of the present disclosure provide for water soluble polyethylene glycol (PEG)-polymeric melanin (PEG-melanin) nanoparticles, methods of using the PEG-melanin nanoparticle, methods of making the PEG-melanin nanoparticle, methods of imaging a diseases or condition (e.g., pre-cancerous tissue, cancer, or a tumor), and the like. Embodiments of the present disclosure can be used in multimodal imaging (e.g., photoacoustic, nuclear, magnetic, fluorescent, and the like). | 12-04-2014 |
20140363374 | COUPLED IDENTIFICATION AND TREATMENT OF CANCER - Provided are methods to treat cancer, in which (1) a patient is first identified as having a cancer that is likely to be susceptible to gallium therapy, by the use of a gallium scan or other procedure that shows whether the cancer is gallium-avid, and (2) the patient is then treated with a pharmaceutically acceptable gallium composition. | 12-11-2014 |
20140377175 | CHEMICALLY-LINKED NANOPARTICLES - Provided herein are compositions and methods of preparing nanoparticle aggregates. | 12-25-2014 |
20140377176 | Functionalised silicon nanoparticles - The present invention is related to silicon nanoparticles, a pharmaceutical composition comprising silicon nanoparticles, a method for synthesis of the silicon nanoparticles and their use for in vivo diagnostics, visualization of drug delivery or staining of cells, biological processes or pathways. The silicon nanoparticles are characterised that they comprise a silicon core of a size of 1 to 10 nm and are terminated with allylamine or poly(allylamine) comprising up to 10 allylamine groups. | 12-25-2014 |
20150010472 | METHOD OF USING ADENOSINE AND DIPYRIDAMOLE FOR PHARMACOLOGIC STRESS TESTING, WITH SPECIFIC COMPOSITIONS, UNIT DOSAGE FORMS AND KITS - Methods for detecting the presence and/or assessing the severity of myocardial ischemia during pharmacologic stress tests by administration of a pharmaceutical composition comprising adenosine and dipyridamole are described. The methods allow for the combined administration of dipyridamole administered as a bolus with adenosine given as an infusion, where the dosages of each of these compounds are below their respective dosages when the compounds are used as a single agent. The methods are useful for exploiting the vasodilating abilities of adenosine at doses at which side effects related to adenosine are substantially reduced while optimal coronary artery perfusion is achieved. Also presented, are compositions, unit dosage forms, and kits that are useful in performing the methods. | 01-08-2015 |
20150017097 | Sincalide Formulations - The invention features sincalide formulations that include an effective amount of sincalide, a bulking agent/tonicity adjuster, a stabilizer, a surfactant, a chelator, and a buffer. The invention also features kits and methods for preparing improved sincalide formulations as well as methods for treating, preventing, and diagnosing gall bladder-related disorders using sincalide formulations. | 01-15-2015 |
20150037252 | Method for the Treatment of a Solid Tumour - The present invention relates generally to a method of treating a neoplastic condition and to agents useful for same. More particularly, the present invention is directed to a method of facilitating the treatment of a solid tumor in a localised manner via the co-administration of particulate material and a cellular toxin. The method of the present invention is useful in a range of therapeutic treatments including the treatment of primary and metastatic tumors. | 02-05-2015 |
20150037253 | METAL COMPLEXES AS IMAGING AGENTS - The present invention relates to copper, gallium and technetium coordinated thiosemicarbazone-pyridylhydrazine (substituted at the pyridine ring with a substituted benzothiazole or stilbene moiety) complexes and methods thereof. Such compounds possess utility in PET imaging and diagnosis of amyloid diseases. | 02-05-2015 |
20150064109 | Quantified differentiation and identification of changes in tissue by enhancing differences in blood flow and metabolic activity - The invention provides a novel quantitative method for differentiating and identification of changes in tissue by enhancing differences in blood flow prior to administering a radiopharmaceutical, which differentially accumulates in tissue based upon differences in blood flow and metabolic activity. In one embodiment the enhancing agent is 0.852 mg per kilogram body weight dipyridamole and the radiopharmaceutical is Technetium-99m hexakis 2-methoxyisobutylisonitrile (sestamibi) and the tissue differentiation is calcification, normal, inflammatory, precancerous and cancerous breast tissue. The present invention allows differentiation between regions of calcification, nonliving or metabolically inactive tissue, normal tissue, pre-cancerous and cancerous tissue. The present invention allows for quantification of changes in tissue to determine the effect of treatment upon tissue. | 03-05-2015 |
20150064110 | CROSSLINKED POLYSACCHARIDE BEADS COMPRISING AN IMAGING AGENT - The present invention relates to a method for preparing beads comprising imaging agent. The present invention further provides beads highly useful for medical imaging. | 03-05-2015 |
20150078997 | N-ALKOXYAMIDE CONJUGATES AS IMAGING AGENTS - The present disclosure is directed to compounds, diagnostic agents, and related methods. In some cases, methods for treating patients are provided. More specifically, the disclosure provides compounds, diagnostic agents, and kits for detecting and/or imaging and/or monitoring elastin rich tissues. In addition, the disclosure provides methods of detecting and/or imaging and/or monitoring the presence of coronary plaque, carotid plaque, iliac/femoral plaque, aortic plaque, renal artery plaque, plaque of any arterial vessel, aneurism, vasculitis, other diseases of the arterial wall, and/or damage or structural changes in ligaments, uterus, lungs or skin, as indicated by changes in total vessel wall area, internal lumen size, and exterior arterial perimeter. | 03-19-2015 |
20150078998 | RADIOLABELED PROSTATE SPECIFIC MEMBRANE ANTIGEN INHIBITORS - Compounds according to Formula I and Formula II are potent inhibitors of PSMA activity: | 03-19-2015 |
20150086479 | LAYERED NANOPARTICLES - The invention provides a process for forming a layered nanoparticle, comprising providing a suspension comprising a core particle in a first liquid, adding a second liquid to the suspension, and adding a reagent, or a precursor for the reagent, to the suspension. The second liquid is immiscible with the first liquid. If the reagent is added to the suspension, the reagent reacts to form a layer on the core particle to form the layered nanoparticle. If a precursor for the reagent is added to the suspension, the precursor is converted to the reagent, and the reagent reacts to form a layer on the core particle to form the layered nanoparticle. | 03-26-2015 |
20150086480 | HETEROARYL INHIBITORS OF PDE4 - The present invention relates to compounds and methods useful as inhibitors of phosphodiesterase 4 (PDE4) for the treatment or prevention of inflammatory diseases and other diseases involving elevated levels of cytokines and proinflammatory mediators. | 03-26-2015 |
20150104387 | PSMA-TARGETING COMPOUNDS AND USES THEREOF - Prostate-specific membrane antigen (PSMA) targeting compounds are described. Uses of the compounds for imaging, therapy, cell sorting, and tumor mapping are also described. | 04-16-2015 |
20150110715 | Double-Labeled Probe for Molecular Imaging and Use Thereof - The present invention relates to a compound or a pharmaceutically acceptable salt thereof having a chemical structure comprising: (A) at least one motif specifically binding to cell membranes of neoplastic cells; (B) at least one chelator moiety of radiometals; and (C) at least one dye moiety; wherein said compound has a molecular weight of not more than 5 kDa. Further, the invention refers to a method for producing such compound and to the in vivo and in vitro uses thereof. | 04-23-2015 |
20150110716 | METHODS OF USING SPECT/CT ANALYSIS FOR STAGING CANCER - A method of evaluating a subject suspected of harboring a prostrate tumor includes administering to the subject an effective amount of a gamma-emitting transition metal complex conjugated to a targeting moiety that selectively binds to prostate-specific membrane antigen (PSMA), including PSMA expressed on the surface of a prostate tumor; subjecting the subject to a nuclear medicine tomographic imaging technique to obtain one or more images of at least a portion of prostate tissue that comprises tumor lesions; assessing a level of uptake of said gamma-emitting transition metal complex conjugated to a targeting moiety by said at least a portion of prostate tissue compared to a level of uptake by control tissue; and determining if a ratio of the level of uptake by said at least a portion of prostate tissue compared the level of uptake by control tissue is at or above a predetermined threshold. | 04-23-2015 |
20150118156 | COMPOSITION AND METHOD FOR THE DIAGNOSIS AND TREATMENT OF DISEASES ASSOCIATED WITH NEURITE DEGENERATION - Provided herein are antibodies and methods of using the antibodies to treat and diagnose neurite degenerative diseases and disorders. | 04-30-2015 |
20150125388 | MOLECULAR PROBES FOR MULTIMODALITY IMAGING AND TRACKING OF STEM CELLS - The invention relates to novel multi-modality probes for imaging, tracking and analyzing stem cells and related biological samples, and methods of preparation and use thereof. The molecular probes of the invention are constructed, for example, by utilizing (a) the high selectivity of long hydrocarbon chains for binding to plasma membranes of cells, (b) a near-infrared (NIR) dye for optical imaging, and (c) a radionuclide for PET or SPECT imaging. The in vitro and in vivo data of the optical and radiolabeled probes demonstrated their utility for detecting the presence of stem cells with multiple imaging modalities. | 05-07-2015 |
20150139901 | Radioactive Rhodium Complexes, Preparation Methods and Uses Thereof - The present invention concerns radioactive rhodium complexes, their preparation methods, and their use for the radiolabelling of biomolecules, especially monoclonal antibodies. | 05-21-2015 |
20150297608 | Tricyclic Lactams for Use as Anti-Neoplastic and Anti-Proliferative Agents - This invention is in the area of tricyclic lactam compounds and methods for treating selected cancers and hyperproliferative disorders. | 10-22-2015 |
20150299133 | NEUROTENSIN RECEPTOR LIGANDS - The present invention is related to a compound of formula (I) wherein R | 10-22-2015 |
20150299212 | Tricyclic Lactams for Use in HSPC-Sparing Treatments for RB-Positive Abnormal Cellular Proliferation - This invention is in the area of tricyclic lactam compounds for and methods of treating selected Rb-positive cancers and other Rb-positive abnormal cellular proliferative disorders while minimizing the deleterious effects on healthy cells, for example healthy Hematopoietic Stem Cells and Progenitor Cells (HSPCs), associated with current treatment modalities. In one aspect, treatment of select Rb-positive cancers is disclosed using specific compounds disclosed herein. In certain embodiments, the compounds described herein act as selective cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors when administered to subjects. | 10-22-2015 |
20150320892 | IMAGING FIBROSIS - The present invention provides a labelled compound suitable for use as an in vivo imaging agent. The in vivo imaging agent of the invention is useful in the in vivo diagnosis and imaging of fibrosis and in particular fibrosis in the liver. Also provided by the present invention is a method for the preparation of the labelled compound of the invention and a precursor compound useful in said method and a kit useful for carrying out said method. In addition, the present invention provides a pharmaceutical composition comprising the labelled compound of the invention as well as a method of in vivo imaging using the labelled compound of the invention, preferably as the pharmaceutical composition of the invention. | 11-12-2015 |
20150343094 | COMPOSITIONS AND METHODS FOR IN VIVO IMAGING - The present disclosure provides lipid-probe compounds, and compositions comprising the compounds. A subject lipid-probe compound is useful for various imaging applications, which are also provided. | 12-03-2015 |
20150359913 | TETRAZINES/TRANS-CYCLOOCTENES IN SOLID PHASE SYNTHESIS OF LABELED PEPTIDES - This invention is in the field of labeled peptide construction for medical treatment and analysis. The invention relates to synthetic labeled peptide compositions, methods of synthesis, and methods of use for the synthetic labeled peptide compositions for medical treatment, imaging, and research purposes. | 12-17-2015 |
20160022844 | TETRAHYDROXAMATE CHELATORS OF ZIRCONIUM89 AND NIOBIUM90 FOR USE IN DIAGNOSTIC APPLICATIONS - Disclosed is a compound of formula (I) or (II) in which R | 01-28-2016 |
20160022845 | SYNTHON COMPOSITION - The present invention relates to an improved [ | 01-28-2016 |
20160030604 | COMPOSITIONS AND METHODS FOR ASSESSING NEUROMUSCULAR FUNCTION - The invention provides compositions and methods for evaluating neuromuscular function in a subject, e.g., a subject at risk for or suffering from a neuromuscular disorder. | 02-04-2016 |
20160051704 | MOLECULAR IMAGING PROBES FOR LUNG CANCER INTRAOPERATIVE GUIDANCE - Molecular probes directed to the delta opioid receptor and associated methods of use as non-invasive diagnostics for lung cancer are presented. The molecular probes generally consist of a ligand (Dmt-Tic) that is conjugated to a detection moiety such as a fluorescent dye or a radionuclide by a linker molecule. Once the probe is administered, it may be detected by a molecular imaging device to locate tumors for treatment or removal. Also presented are novel markers for lung cancer including, but not limited to, CA9, CA12, CTAG2, CXorf61, DSG3, FAT2, KISS1R, GPR87, LYPD3, OPRD1, SLC7A11 and TMPRSS4. Probes may be developed that can target these cell surface markers. | 02-25-2016 |
20160067360 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS - The present application provides for a compound of Formula I, | 03-10-2016 |
20160115180 | Novel Super-Resolution Imaging Compositions and Methods Using Same - The invention provides compositions that may be used for imaging intracellular structures. The invention further provides methods of imaging intracellular structures. In certain embodiments, the compositions of the invention include trans-cyclooctene-containing ceramide lipids and tetrazine-containing rhodamine-related dyes. | 04-28-2016 |
20160121003 | METHODS FOR DIAGNOSING AND MONITORING TREATMENT OF LEWY BODY DEMENTIA BY ASSESSING DOPAMINE TRANSPORTER LEVEL - A method of diagnosing Lewy Body Dementia in a human patient by assessing the level of dopamine transporter in at least one region of the patient's central nervous system, where a lowered level of dopamine transporter in the patient is indicative of Lewy Body Dementia. In embodiments of the invention, assessment of dopamine transporter levels includes assessing binding of a dopamine transporter ligand to the dopamine transporters using PET or SPECT. | 05-05-2016 |
20160145259 | CXCR7 ANTAGONISTS - Compounds having formula I, | 05-26-2016 |
20160158391 | IMAGE GUIDED BORONATED GLUCOSE NEUTRON CAPTURE THERAPY - Disclosed herein are methods, processes, devices, and compositions for the treatment of target cells and/or tissues, the treatment comprising identifying the target cell with positron emission tomography and then directing a epithermal neutron toward the identified target cell. In various aspects, the target cells and/or tissues take up and metabolize boronated glucose and radioactive fluorinated glucose molecules. | 06-09-2016 |
20160175465 | PET IMAGING OF ZINC TRANSPORT | 06-23-2016 |
20160250359 | HIGH PURITY THERAPEUTIC BONE AGENTS | 09-01-2016 |
20160375157 | COMPOSITIONS FOR TARGETED IMAGING AND THERAPY - The present invention relates to the field of radiochemistry, nuclear imaging, radionuclide therapy and chemical synthesis. More particularly, it concerns a strategy for radiolabeling target ligands. It further concerns methods of using those radiolabeled ligands for imaging, radionuclide therapy and tissue-specific disease imaging. | 12-29-2016 |
20180022748 | 9H-PYRROLO-DIPYRIDINE DERIVATIVES | 01-25-2018 |